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A prevalência das doenças alérgicas tem vindo a aumentar nas últimas décadas, 
especialmente nos países industrializados. Estas doenças surgem em indivíduos 
geneticamente predispostos, sob influência de factores ambientais. A “hipótese higiénica” 
procurou explicar este aumento de prevalência, relacionando-o com uma diminuição do 
contacto com microrganismos e do número de infecções, características do modo de vida 
ocidental. Inicialmente, pensou-se que a redução do contacto com microrganismos impedia 
o desvio imune de respostas do tipo T auxiliar 2 (“T helper 2” ou Th2)  para respostas do 
tipo Th1, que ocorre geralmente com a idade (de acordo com o paradigma Th1/Th2). A 
inflamação, que ocorre particularmente ao nível das vias aéreas na asma e na rinite seria 
resultado de uma perda de equilíbrio entre respostas do tipo Th1, importantes nos 
mecanismos de defesa intracelular e respostas do tipo Th2, que caracterizam a inflamação 
alérgica. No entanto, estudos epidemiológicos posteriores puseram esta interpretação em 
causa. Foi então sugerido que, por diminuição da actividade reguladora/supressora dos 
linfócitos T, ocorre não um desvio imune, mas sim um desenvolvimento de respostas 
inadequadas face a estímulos antigénicos, resultando quer em doenças alérgicas quer em 
doenças auto-imunes.  
A atopia consiste numa predisposição genética para produzir anticorpos IgE contra 
antigénios ambientais comuns (alergénios) e correlaciona-se com o desenvolvimento de 
uma ou mais doenças alérgicas. Estas caracterizam-se pela infiltração ao nível do órgão-alvo 
de células inflamatórias activadas, das quais se destacam os eosinófilos, os mastócitos e os 
linfócitos T.  
De facto, as células T, especialmente as células T CD4+ do tipo Th2, são consideradas as 
grandes orquestradoras da resposta alérgica. As suas funções são mediadas principalmente 
pela secreção de citocinas do tipo 2 (interleucina (IL)-4, IL-5, IL-9 e IL-13). 
Posteriormente, foi mostrado que também células T CD8+ eram capazes de sintetizar estas 
citocinas (padrão “T cytotoxic 2” ou Tc2). No entanto, o papel desempenhado pelas células 
T CD8+ na doença alérgica ainda não está bem esclarecido. Diversos estudos, 
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nomeadamente em modelos animais, referem resultados contraditórios, atribuindo às 
células T CD8+ quer funções reguladoras, quer funções promotoras da inflamação.  
A existência de subpopulações de células T CD8+ com características fenotípicas e 
funcionais distintas poderá ser um dos motivos para esta disparidade de resultados. 
Estudos efectuados em indivíduos atópicos sugeriram que as células T CD8+ poderiam 
estar envolvidas no desenvolvimento de asma alérgica. Células T CD8+ estavam presentes 
nos infiltrados celulares no órgão-alvo, sendo que esta presença se correlacionava com 
asma severa e morte por asma brônquica. No entanto, estudos noutras patologias 
relacionaram a existência de células T do tipo CD8+ com funções reguladoras. A evidência 
é mais relevante em casos de transplantes de órgão sólido, onde a presença de células T 
supressoras do tipo CD8+CD28− se correlaciona com aumento de tolerância ao 
transplante e menor necessidade de medicação imunossupressora. 
Tendo em atenção estes e outros estudos prévios, procurámos, neste estudo, clarificar o 
papel das células T CD8+ na atopia, nomeadamente no que diz respeito ao seu fenótipo e 
função na asma e rinite alérgicas. Definimos cinco objectivos: avaliar a proliferação 
alergénio-específica e a síntese de citocinas por células T CD8+; verificar se as células T 
CD8+ isoladas do sangue periférico têm propriedades supressoras face a respostas 
alergénio-específicas; verificar se as células T CD8+ estão presentes ao nível do órgão-alvo 
e se se encontram activadas; observar se existe correlação entre a expressão dos marcadores 
de activação expressos por células T CD8+ e a severidade da asma ou o seu controlo e por 
último, pretendemos caracterizar demograficamente a nossa população de estudo.  
De modo a contextualizar os resultados a nível celular, decidimos iniciar o nosso estudo 
pela caracterização epidemiológica da população alvo (doentes com rinite alérgica e doentes 
com asma brônquica alérgica). Apesar do número de publicações sobre prevalência, 
diagnóstico e tratamento das doenças alérgicas ter aumentado nos últimos anos, dados 
relativos aos perfis de sensibilização continuam escassos. Dados relativos a prevalência em 
crianças foram obtidos maioritariamente através do estudo ISAAC (“International Study on 
Asthma and Allergy in Children”) nas suas diversas fases. Neste estudo, os dados relativos a 
Portugal mostram um aumento da prevalência na rinoconjuntivite alérgica e na asma 
brônquica em ambos os grupos etários de crianças (6-7 anos e 13-14 anos) entre as fases I e 
III, separadas no tempo por sete anos.  
Relativamente aos dados na população adulta, Portugal participou no estudo ECHRS 
(“European Community Respiratory Health Survey”), que avaliou, através de questionário, 
 
 xi
adultos entre os 20 e os 44 anos. Dados relativos a este estudo estimam uma prevalência de 
asma de cerca de 5% e de rinite de 17% para a população avaliada. 
Apesar da região da Cova da Beira ter dos mais altos níveis polínicos a nível nacional 
(como descrito no Mapa Polínico de Portugal (1998-1999), neste momento não está incluída 
na Rede Portuguesa de Aerobiologia, nem existe nenhuma estação de monitorização de 
pólenes na região. Os dados sobre doença alérgica, especificamente relativos à região da 
Cova da Beira são muito escassos, revelando esforços mais ou menos individuais para 
clarificar a situação em termos de prevalência, sensibilizações e severidade de patologia. 
Pareceu-nos, pois, essencial caracterizar a doença alérgica na Cova da Beira de um modo 
mais sistematizado, como complemento importante dos nossos estudos de Imunologia 
básica da Alergia. 
Recolhemos dados relativos aos doentes da consulta de Imunoalergologia do Hospital da 
Cova da Beira, centrando-nos especificamente em doentes com asma brônquica e rinite 
alérgica. Para o estudo da asma brônquica foram incluídos doentes admitidos à Consulta de 
Imunoalergologia entre 2003 e 2006 (1078 doentes), enquanto o estudo da rinite incluiu 
doentes admitidos à Consulta de Imunoalergologia entre 2003 e 2007 (1092 doentes). Para 
a análise posterior foram excluídos doentes com menos de 18 anos, doentes não residentes 
no concelho e todos aqueles com resultados laboratoriais discordantes em termos de 
avaliação de alergia.  
A asma brônquica é uma doença inflamatória crónica, caracterizada por obstrução 
intermitente, reversível espontaneamente ou mediante tratamento e por hiper-reactividade 
brônquica. A rinite é também uma doença com características inflamatórias, caracterizada 
clinicamente por rinorreia, obstrução nasal e crises esternutatórias. Apesar dos avanços no 
conhecimento da sua fisiopatologia e terapêutica, a asma e a rinite mantém-se como duas 
das doenças crónicas mais frequentes em crianças e adultos. 
O diagnóstico da asma e da rinite foi feito com base numa história clínica positiva e no 
exame objectivo (incluindo rinoscopia anterior), suportado por testes específicos de alergia 
(testes cutâneos por picada e determinação de IgE específica sérica), bem como por provas 
funcionais ventilatórias, no caso da asma brônquica. De acordo com a presença ou não de 
processos mediados pela IgE, os doentes foram divididos em duas grandes categorias: 
alérgicos e não alérgicos. Para a classificação de aspectos ligados à severidade da doença e 
ao seu controlo foram aplicadas “guidelines” internacionais (“Global Initiative for Asthma” para 
a asma e “Allergic Rhinitis and its Impact on Asthma” para a rinite). 
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Foram também avaliadas as principais co-morbilidades da asma e da rinite, nomeadamente 
no que diz respeito ao conceito actual de “one airway one disease” que considera asma e rinite 
manifestações de uma mesma entidade. Especificamente, doentes com rinite foram 
avaliados quanto à presença de asma pela história clínica, exame objectivo do tórax e 
avaliação de obstrução e, do mesmo modo, doentes com asma foram avaliados quanto à 
presença de rinite pela história clínica e rinoscopia anterior. 
Trinta por cento dos doentes asmáticos e vinte e oito por cento dos doentes com rinite 
eram não alérgicos. Globalmente, os doentes não alérgicos eram mais velhos, 
predominantemente do sexo feminino e com uma maior prevalência de alergia/intolerância 
medicamentosa. Como descrito atrás e de acordo com as “guidelines” do projecto ARIA 
(“Allergic Rhninitis and its Impact on Asthma”), verificámos a associação de asma e rinite. Na 
população em estudo, a rinite estava mais frequentemente associada com a asma não 
alérgica do que com a asma alérgica. Pelo contrário, a asma brônquica estava 
preferentemente associada com rinite alérgica. No primeiro caso, estes resultados podem 
dever-se ao facto da rinite alérgica geralmente preceder o desenvolvimento de asma alérgica 
(marcha atópica). De facto, a imunoterapia específica parece atrasar ou mesmo impedir a 
progressão da rinite alérgica para asma. Pelo contrário, não existe esta progressão temporal 
quando se fala de doença não alérgica, em que geralmente existem desencadeantes comuns. 
Os dois tipos de asma e de rinite (alérgica e não alérgica) não puderam ser distinguidos em 
termos de severidade da doença, nem em termos de sintomatologia clínica. Este facto era 
inesperado, uma vez que estudos anteriores mostravam que asma e rinite não alérgicas 
eram mais severas do que quando se deviam a alergia. Contudo, não podemos descurar que 
esta conclusão possa ter tido origem num viés na análise: geralmente a severidade da 
doença aumenta com a idade e os doentes com patologia não alérgica são mais velhos, pelo 
que, em estudos de amostras não emparelhadas quanto à idade, a patologia não alérgica vai 
parecer mais severa. 
 
Os alergénios mais frequentes na região são os pólenes de gramíneas (Poaceae), sejam elas 
cultivadas ou não, os ácaros e os pólenes de oliveira. A monosensibilização não é comum e, 
nos casos em que existe, refere-se unicamente a alergia a ácaros. Um dado interessante 
prende-se com o facto de os pólenes das gramíneas não serem apenas responsáveis pela 
maioria das sensibilizações, mas serem também os responsáveis pelos níveis mais elevados 
de IgE específica. No entanto, não foi possível estabelecer uma correlação entre os níveis 
de IgE específica e a severidade da asma ou da rinite. 
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Estudos semelhantes levados a cabo noutras regiões mostraram uma associação 
significativa entre os níveis de poluição atmosférica e o aumento da sintomatologia ligada à 
asma e à rinite. A prevalência de atopia e doença alérgica era maior nas zonas urbanas do 
que nas zonas rurais, devido quer a um aumento da poluição atmosférica nas zonas 
urbanas, quer a um efeito protector do ambiente rural. Nas áreas urbanas, os grãos de 
pólen podem ficar revestidos com resíduos de combustível e com produtos da combustão, 
sendo que esta ligação a partículas de exaustão de diesel pode alterar os epítopos 
alergénicos e mesmo aumentar a sua alergenicidade. Convém salientar que irritantes não 
específicos como a poluição atmosférica são capazes de agravar ou mesmo induzir 
sintomas em doentes asmáticos. 
No nosso estudo, asmáticos residentes em ambiente rural ou urbano apresentavam perfis 
de sensibilização distintos, tendo, no entanto severidades da doença semelhantes. Doentes 
com rinite alérgica apresentavam perfis de sensibilização semelhantes. Estes resultados 
podem ser explicados pelo tamanho relativo dos grãos de pólen que condiciona a sua 
passagem pelas vias aéreas. Geralmente, grãos de pólen intactos são incapazes de penetrar 
as regiões mais distais das vias aéreas, sendo a maioria dos sintomas localizados ao nível 
dos olhos, nariz e faringe. No entanto, alergénios derivados dos grãos de pólen podem 
depositar-se em partículas sub-micrónicas e desencadear asma, tal como ocorre durante as 
trovoadas. 
 
Os nossos estudos epidemiológicos forneceram uma base de trabalho extensa e 
pormenorizada da nossa população, permitindo delinear melhor os estudos celulares 
subsequentes. Por outro lado, estes estudos vieram reforçar a necessidade de tratar em 
conjunto doenças das vias aéreas superiores e inferiores usando uma estratégia 
simultaneamente mais eficaz e mais segura. No entanto, estes estudos apresentam uma 
importante limitação, visto analisarem amostras provenientes de uma consulta da 
especialidade. De um modo geral, a maioria dos doentes seguidos em consultas da 
especialidade são aqueles em que a severidade da doença é maior. Outro ponto a considerar 
prende-se com a classificação da severidade da doença. Apesar de esta ter sido efectuada na 
primeira consulta, alguns dos doentes já se encontravam sob medicação, o que poderia 
enviesar a classificação. 
De qualquer forma, trata-se, na nossa opinião, de um estudo muito interessante uma vez 
que inclui parâmetros clínicos, contrastando com a maioria dos estudos anteriores que 





CÉLULAS T CD8+ NA ALERGIA 
 
A asma e a rinite alérgicas caracterizam-se pela presença de uma inflamação crónica 
mediada por múltiplas proteínas inflamatórias, incluindo citocinas, quimiocinas e enzimas. 
Em ambas as patologias ocorrem exacerbações quando a intensidade da inflamação 
aumenta. Diversos estudos sugeriram que as células T desempenham um papel 
fundamental nesta inflamação. Através da síntese e secreção de citocinas do tipo 2, as 
células T promovem a diferenciação de células Th2 e a síntese de IgE pelas células B (IL-4 
e IL-13); promovem a diferenciação, a activação e a sobrevivência dos eosinófilos (IL-5) e 
aumentam a diferenciação de mastócitos e a produção de muco (IL-9). Tal como foi 
referido, a grande maioria dos estudos avaliou fenotípica e funcionalmente as células T 
CD4+, sendo escassos os resultados relativos às células T CD8+. 
Uma vez que a atopia se caracteriza por elevados níveis de IgE específica sérica, muito 
provavelmente alterações no órgão-alvo vão reflectir-se ao nível do sangue periférico. O 
estudo das células T CD8+ do sangue periférico de doentes alérgicos constituiu o nosso 
primeiro projecto ao nível da imunologia básica da doença alérgica. Uma vez que a 
expressão da molécula co-receptora CD28 permite definir duas subpopulações distintas ao 
nível das células T CD8+, procurámos, ao longo do estudo, aprofundar a sua 
caracterização fenotípica e funcional.  
As células T foram isoladas a partir de sangue periférico de doentes com asma e/ou rinite 
por centrifugação em gradiente de densidade. Em seguida, as células T CD8+CD28+ e 
CD28− foram isoladas por separação imunomagnética num sistema semi-automático 
(MACS®) e usadas, posteriormente, para os estudos funcionais. Para avaliar a proliferação 
e síntese de citocinas em resposta a aeroalergénios usámos extracto purificado de 
Dermatophagoides pteronyssinus. Para avaliar a capacidade supressora das células T CD8+ face 
às respostas alergénio-específicas desenvolvemos um sistema de co-culturas com células 
mononucleares do sangue periférico tratadas com mitomicina. A pureza das fracções 
usadas foi avaliada por citometria de fluxo. 
Observámos que a atopia não estava relacionada com alterações nas percentagens ou 
fenótipo das células T CD8+; no entanto, células T CD8+CD28+ eram distintas em 
termos fenotípicos de células T CD8+CD28−. Esta alteração fenotípica era acompanhada 
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por uma resposta proliferativa distinta relativamente a mitogénios e alergénios, se bem que 
semelhante do ponto de vista da secreção de citocinas. 
Ambas as subpopulações apresentavam uma capacidade proliferativa semelhante em 
doentes atópicos e não atópicos e não apresentavam características supressoras. 
Estes resultados devem, no entanto, ser analisados com cuidado, uma vez que as culturas in 
vitro não conseguem imitar o estímulo repetido e prolongado que ocorre in vivo. Além disso, 
as células T do sangue periférico não partilham o mesmo ambiente das células T dos 
órgãos-alvo, não estando sujeitas ao mesmo tipo de interacções e contacto com alergénio. 
Para clarificar se o que ocorre ao nível do sangue periférico reflecte o que se passa no 
órgão-alvo, procurámos estudar células T CD8+ provenientes deste. Procurando uma 
abordagem menos invasiva do que os lavados broncoalveolares ou as biópsias, realizámos o 
estudo em células T provenientes da expectoração induzida de doentes asmáticos alérgicos. 
Foram incluídos no estudo asmáticos alérgicos com asma intermitente ou moderada 
persistente com diversos graus de controlo. 
A expectoração induzida foi obtida por inalação de uma solução hipertónica salina (NaCl a 
5%). A expectoração foi seguidamente homogeneizada e incubada com ditiotreitol, sendo 
posteriormente filtrada através de um filtro celular de 0.40μm de diâmetro de poro. A 
viabilidade da suspensão celular obtida foi avaliada pelo método de exclusão de Azul 
Tripano em câmara de Neubauer. 
Neste estudo mostramos claramente que, quer as células T CD4+, quer as células T CD8+ 
apresentam um fenótipo activado na expectoração induzida, o que sugere que ambas as 
subpopulações celulares participam no processo inflamatório ao nível do órgão-alvo. Uma 
vez que esta inflamação se relaciona com a severidade da doença, procurámos avaliar a 
correlação existente entre a activação celular e o grau de severidade da asma. 
Apesar da escolha criteriosa de voluntários, emparelhados quanto a sexo, idade e controlo 
da doença, não observámos correlação entre a percentagem relativa de expressão de 
marcadores de activação (CD25 e CD69) e o grau de severidade da doença. 
Atendendo a que o controlo é um dos objectivos mais determinantes do tratamento da 
asma, avaliámos também a correlação existente entre os nossos marcadores de activação 
em estudo e o controlo da doença. Optámos aqui por incluir apenas asmáticos alérgicos 
com asma moderada persistente, sob tratamento mais ou menos equivalente. Tal como se 
verificou com a severidade, também não se observou correlação entre a percentagem 
relativa dos marcadores de activação e o controlo da doença.  
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Para clarificar o efeito dos corticosteróides inalados na expressão dos marcadores de 
activação, comparámos a percentagem relativa dos marcadoress de activação entre 
asmáticos com asma intermitente controlados e não controlados. Não observámos 
correlação entre a percentagem relativa dos marcadores e o grau de controlo dos doentes, o 
que parece indicar um efeito mínimo dos corticosteróides inalados em termos de avaliação 
de controlo da asma. 
 
Em resumo, nesta Tese clarificámos as características demográficas da população de 
asmáticos e doentes com rinite da consulta de especialidade do Hospital Pêro da Covilhã e 
caracterizámos as células T, especialmente da população T CD8+ nestes indivíduos em 
termos fenotípicos e funcionais. Finalmente, procurámos novas estratégias para isolar 
células T do sangue periférico e diferenciar linhas celulares T alergénio-específicas. 
Relativamente às nossas hipóteses iniciais, verificámos que as células T CD8+ isoladas a 
partir do sangue periférico não apresentavam características supressoras das respostas 
alergénio-específicas. Em segundo lugar, as células T CD8+ da expectoração induzida de 
doentes asmáticos expressavam marcadores de activação, sendo a percentagem relativa de 
expressão maior do que a encontrada ao nível do sangue periférico. No entanto, embora 
apresentando um fenótipo de células activadas, a percentagem relativa dos marcadores de 





The prevalence of allergic diseases has been increasing during the last decades. It is 
believed that the development of allergic diseases in susceptible individuals is dependent on 
T cells, especially type 2 CD4+ T cells. CD8+ T cells may also be involved in the 
pathophysiology of allergic diseases, albeit studies in animal models of asthma have found 
confounding results. 
With our study we attempted to clarify the phenotypic and functional properties of CD8+ 
T cells in allergic disease settings. The specific aims were to assess allergen-specific 
proliferation and cytokine synthesis of CD8+ T cells and evaluate their suppressor function 
on antigen-specific responses. In addition, it was also our goal to assess the presence of 
CD8+ T cells at the target organ and their activation status, correlating our findings with 
disease severity and control. In order to contextualize our cellular findings, we initially 
characterised our study population from an epidemiological point of view. 
We enrolled asthma and rhinitis patients attending the Allergy Clinic of the Cova da Beira 
Hospital. Asthma and rhinitis were diagnosed by a positive clinical history and specific 
diagnostic tests, and severity was assessed by current guidelines. We also identified the 
main co-morbidities in both disease settings and evaluated asthma symptoms in rhinitis 
patients and rhinitis symptoms in asthma patients. In the allergic groups we investigated the 
sensitisation profiles to aeroallergens and concluded that major allergens included grass and 
cereal pollen, mites and olive tree pollen. Sensitisation profiles and severity were also 
compared between rural and urban-based allergic patients. In this regard, we found 
contrasting results between asthmatic patients and patients with rhinitis. 
In the second part of our study we clarified the role of CD8+ T cells in allergic 
inflammation through basic cellular systems. We assessed proliferation capacity and 
cytokine synthesis in response to Dermatophagoides pteronyssinus extract, and devised a 
co-culture system in order to evaluate the suppressor function of CD8+ T cells. 
CD8+CD28+ and CD28− T cells isolated from the peripheral blood had distinct 
phenotypes and proliferated at different levels to common stimuli, although sharing similar 
cytokine production patterns. A potential suppressor activity was not found in the 
co-culture systems, either for CD8+CD28+ or CD28− T cells. 
We then studied CD8+ T cells at the target-organ, assessing activation phenotype in cells 
from the induced sputum of asthmatic patients. We showed that CD8+ T cells are 
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activated at the target-organ, although we were unable to demonstrate a relationship 





ACT Asthma Control Test 
AHR Airway hyperresponsiveness 
AICD Activation induced cell death 
APC Antigen presenting cell 
-APC Allophycocyanin conjugated 
AR Allergic rhinitis 
ARIA Allergic Rhinitis and its Impact on Asthma 
BAL Bronchoalveolar lavage 
BSA Bovine serum albumin 
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CD Cluster of differentiation 
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GINA Global Initiative for Asthma 
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mAb Monoclonal antibody 
MHC Major histocompatibility complex 
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NK Natural killer 
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PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
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PBS Phosphate buffered saline 
-PE Phycoerythrin conjugated 
PEF Peak expiratory flow 
-PerCP Peridinin chlorophyll protein conjugated 
PHA Phytohaemagglutinin 
PMA Phorbol myristate acetate 
sem Standard error of the mean 
Tc T cytotoxic cells 
TCC  T cell clones 
TCL T cell lines 
TCM Central memory CD8+ T cell 
TCR T cell receptor 
TEFF Effector memory CD8+ T cell 
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This Thesis is divided into five chapters.  
The first chapter consists of a brief literature review running from atopy and allergic 
diseases to specific issues regarding CD8+ T cells in allergy settings.  
The second chapter includes an overview of the methods used.  
Subsequently, the third chapter is based on original research papers published or submitted 
during the Ph.D. course, and directly related to this Thesis.   
The fourth chapter comprises the general discussion and conclusion remarks.  
Finally, the fifth chapter refers to unpublished work developed during the course and 














1.1. Atopy and Allergic Diseases 
 
Atopy is an individual predisposition for excessive immunoglobulin (Ig)-E production 
against harmless environmental allergens. It is a genetically and environmentally determined 
condition 1, 2, which may lead to allergic diseases such as asthma, allergic rhinitis, 
conjunctivitis, and atopic dermatitis 3. It is estimated that as many as 300 million people of 
all ages, and all ethnic backgrounds, suffer from asthma and the burden of this disease to 
governments, health care systems, families, and patients is increasing worldwide 4. 
The prevalence of allergic diseases has been increasing during the last decades, especially in 
developed countries. The “hygiene hypothesis” attempts to explain this increase on the 
basis of reduced exposure to infectious agents, especially during early life. Early studies 
suggested that a skewing of the T cell response towards type 2 CD4+ T cells could explain 
the subsequent development of allergy 5. Inflammation, particularly in the airways in 
asthma and rhinitis would represent a loss of balance between T-helper (Th)-1 cells, critical 
for intracellular defence mechanisms, and Th2 cells, which mediate allergic inflammation.  
However, several observations argue against this. Firstly, epidemiological studies showed 
that both Th2-related allergies and Th1-related autoimmune diseases could co-exist in the 
same populations 6, 7. Secondly, high parasite burdens, which are associated with strong Th2 
responses, seem to protect against allergic disease 8, 9. Thirdly, in asthma, IFN-γ levels are 
enhanced, suggesting that Th1 cytokines contribute to the pathogenesis of the disease, 
instead of protecting from it 10, 11. 
The first interpretation of the “hygiene hypothesis” states that a reduced microbial burden 
impairs the shift of allergen-specific responses from the Th2 to the Th1 phenotype that 
usually takes place with age (thereby failing to undergo immune deviation). The more 
recent interpretation states that the lower microbial burden reduces the activity of 
regulatory T cells leading to allergy and autoimmunity (reduced immune suppression). 
(For review on the “hygiene hypothesis” see 12, 13, 14).  
 
It is generally believed that the development of allergic disease in susceptible individuals 
first requires repeated and persistent exposure to allergens, leading to aberrant activation 
and recruitment of T cells with subsequent differentiation of increased numbers of 
allergen-specific Th2 cells. These T cells provide interleukin (IL)-4 and contact-mediated 
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signals that promote differentiation of B cells and class-switching to the production of IgE. 
The produced IgE binds to high affinity IgE receptors (FcεRI) on the surface of circulating 
basophils and on mast cells in various tissues. Following such sensitisation, subsequent 
exposure to the specific allergen initiates a secondary immune response. The allergen binds 
to cell-associated IgE and cross-links the IgE molecules and the FcεRI receptors to which 
they are bound. Cross-linking of the IgE-FcεRI complexes on basophils and mast cells 
signals these cells to release preformed and newly generated mediators, including biogenic 
amines such as histamine, lipid mediators such as leukotrienes, and cytokines (early phase 
response) 15. Biogenic amines and lipid mediators create the signs and symptoms of allergic 
disease that typically begin within one hour of allergen exposure. These include rapid 
vascular leakage of plasma fluid and protein, and vasodilatation. Six to twenty-four hours 
later, a second round of symptoms (late phase reaction) may develop, mainly driven by the 
release of cytokines and chemokines. Specifically, in terms of target-organs, in the nose, 
this late reaction is characterised by an inflammatory infiltrate including activated 
eosinophils, basophils, neutrophils, and lymphocytes; resulting in major congestion, itching 
and rhinorrhea 2. Furthermore, in the lung, repeated episodes of this late phase reaction can 
lead to tissue damage and remodelling. 
Antigen presenting cells (APC) including monocytes, macrophages, B cells, dendritic and 
Langerhans cells are important in IgE-mediated allergic responses.  Both the high affinity, 
FcεRI, and the low affinity FcεRII (CD23) IgE receptors are expressed on these APC and 
are important in facilitating allergen presentation to allergen-specific T cells. Triggering of 
the CD23 receptor by IgE on B cells not only enhances antigen presentation, but also 
increases synthesis of IgE. 
The priming of allergen-specific CD4+ T cells and their differentiation towards a Th2 
phenotype are key events for the development of allergic diseases. Th2 cells orchestrate 
atopic inflammation through the secretion of a subset of cytokines, mainly IL-4, IL-5, IL-9 
and IL-13. Similarly, CD8+ T cells from atopic patients have the capacity to produce 




1.2. CD8+ T Cells 
 
CD8+ T cells are major histocompatibility complex (MHC) class I-restricted. As MHC 
class I molecules contain mainly peptides derived from the cytosol, this is an effective 
mechanism for killing cells infected with viruses or other intracellular pathogens. Antigen 
recognition by naïve CD8+ T cells triggers a programme of proliferation and 
differentiation that leads to the production of effector lymphocytes (cytotoxic T 
lymphocytes or CTL) directly able to lyse antigen-bearing cells. The lytic mechanism 
primarily involves release of cytoplasmic granules loaded with perforin (a pore-forming 
protein) and granzyme B (a serine protease) at the contact site between the CTL and the 
target cell 17, resulting in specific killing without bystander cell damage. The nonsecretory 
mechanism is initiated by receptor-mediated triggering of apoptosis-inducing target cell 
surface molecules (Fas-FasL)17. 
However, CD8+ T cells have also been associated with suppression of immune responses, 
and their ability to produce various cytokines, such as IFN-γ and TNF-α, suggests an 
additional function. 
Generally, the peptides bound in the grooves of the MHC class I molecules are derived 
from proteins synthesised within the cell that bears the class I molecules (self-proteins and 
viral proteins); in contrast, allergic responses are thought to occur when CD4+ T cells react 
to exogenous antigen presented on MHC class II molecules. It was believed that CD8+ T 
cells were unable to respond to allergens. However, both macrophages and dendritic cells 
(DC) have been reported to cross-present exogenous antigen to CD8+ T cells in some 
circumstances, by at least two different mechanisms (the phagosome-to-cytosol pathway 
and the vacuolar pathway)(for review see 18). 
Altough most allergens are proteins, some are lipids or carbohydrates. Peptides are not the 
only target of T cell responses, as T cells can recognize lipid antigens through a 
CD1-dependent pathway. In fact, lipids are important in pollen grain structure and 
function, and may be relevant in enhancing grain capture by DC, which is likely to be 
required for their subsequent recruitment of pollen-specific T cells in sensitised subjects 19. 
So, a potential pathogenic role can be envisioned for CD1-restricted T cells, as lipid 
components of allergens can be presented by epithelial DC to T cells 20. T cell clones 
specific for pollen lipids secrete both type 1 and type 2 cytokines and display helper 
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function for IgE production 19. CD1-restricted T cells can be TCR-αβ, -γδ, or NKT cells, 
but the majority of lipid-specific clones decribed to date are CD4+ 19, 21. 
 
Memory and Naïve CD8+ T cells 
 
Immune responses to viral infections involve the proliferation and differentiation of CD8+ 
T cells into an effector population that controls viral replication. The expansion of the 
effector cells is accompanied by an increased sensitivity to apoptosis, which regulates 
proliferation and maintains lymphocyte homeostasis. A small proportion of activated 
CD8+ T cells survive, forming the memory populations. Memory CD8+ T cell subsets 
have been broadly divided into central memory CD8+ T cells (TCM) and effector memory 
CD8+ T cells (TEFF) distinguishable by phenotype and function. TCM reside in lymphoid 
organs, do not express immediate lytic functions, are CD62hiCCR7hi and can be generated 
following culture with IL-15 after a short stimulation with allergen 22. TEFF are found in 
non-lymphoid tissues, express lytic activity, are CD62loCCR7lo and are generated in culture 
with IL-2 22. TEFF can play a critical role in the development of airway hyperresponsiveness 
(AHR) and allergic inflammation by producing IL-13 in the lung.  
When activated under optimal conditions, these cells will emerge as functionally competent 
CTL that are armed with various effector mechanisms to eliminate abnormal cells. There 
are two mechanisms of cytotoxicity: a membranolytic one, depending on the formation of 
pores in the target cell membrane, and mediated by perforin and granzymes; and a 
nonsecretory one, receptor-mediated (Fas-FasL) 17.  Helper CD4+ T cells may not be 
required to initiate CTL activity but are critical for preserving antigen-specific CD8+ T cell 
responsiveness during chronic infection. Since some pathogens are able to directly 
stimulate APC to properly present antigen to CD8+ T cells, helper cells may not be 
required to activate APC during the early stages of infection. During persistent infection, 
where antigen may be minimal and thus unable to effectively condition professional APC, 
CD4+ T cells play a critical role in sustaining CD8+ T cell immunity by activating the APC 
to properly stimulate CD8+ T cells 23, 24. 
In humans, the CD45RA and CD45R0 surface antigens have been used to separate T cells 
into naïve and memory pools. However, discrimination based only on CD45 isoform 
expression is insufficient since, with time, some CD45R0 T cells may revert to CD45RA 25. 
Furthermore, naïve CD8+ T cells are responsive to IL-15 in an antigen-independent way, 
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with concomitant phenotypic changes and acquisition of functional properties (IFN-γ and 
TNF-α synthesis, and cytotoxic function) that are difficult to distinguish from 
antigen-primed T cells 26. 
 
Tc1 and Tc2 cells 
 
The current model of naïve T cell activation postulates that full activation requires two 
signals. The first signal is antigen displayed by the APC in the form of peptides bound to 
histocompatibility molecules; the recognition of antigen by the T cell receptor (TCR) 
provides specificity to the response. The second signal, called the costimulatory signal, is 
provided by molecules on the APC that engage particular costimulatory receptors on T 
cells 27. It can dictate the fate of the response and provides a mechanism for regulating the 
appropriateness of a given response. A third signal or polarization directs T cell 
differentiation into various effector types, such as Tc1 and Tc2; it can be derived from 
cytokines or from inflammatory signals supplied by Toll-like receptor (TLR) ligands 28, 22.  
 
CD8+ T cells can differentiate into two effector phenotypes, Tc1 and Tc2, secreting 
different cytokine patterns. Tc1 cells are defined as CD8+ T cells that secrete IFN-γ but 
not IL-4 or IL-5, and Tc2 cells are CD8+ cells that secrete IL-4, IL-5, and low amounts of 
IFN-γ 29, 30. The synthesis of IL-2 by mouse Tc1 cells is subjected to further regulation, and 
IL-6 and IL-10 are preferentially, but not exclusively, synthesized by Tc2 cells 29. Overall, 
CD8+ T cells are able to produce the same range of type 1 and type 2 cytokines as CD4+ 
T cells 31. 
Naïve CD8+ T cells show a strong preference for differentiating into Tc1 cells. Tc2 
differentiation requires substantial amounts of IL-4 and is very much dependent upon the 
APC 29, whereas IFN-γ and IL-12 encourage differentiation to Tc1 cells 30. 
Human Tc1 CD8+ T cell clones express little CD28, CD30 or CD40L, while Tc2 cells 
express significant amounts of these ligands, which may facilitate their interaction with 
other immune cells 32. 
Both subsets are cytotoxic via the perforin and the Fas pathways, and both are able to kill 
resting and activated B cells 29, 30. Furthermore, both subsets induce inflammation with 
similar cellular infiltrates 29.   
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The CTL response to acute infection can generally be divided into four phases. During the 
effector phase, naïve CTL precursors are primed, undergo dramatic expansion, acquire 
effector function, travel to sites of infection, and mediate pathogen clearance by killing 
infected cells and secreting effector cytokines. During the contraction phase, most effector 
CTL die, leaving behind 5-10% of the original burst size as long-lived memory cells. 
During the memory maintenance phase, memory CTLs are maintained at stable levels 
throughout the mouse lifespan and for many years in humans. The rapid recall response of 
memory CTL following re-exposure to the pathogen provides enhanced protection to the 
host. 
It is unlikely that CD8+ T cells provide help for B cells, since, via the regular 
antigen-processing pathways, foreign antigens would be presented on MHC class II in the 
B cells leading to help by CD4+ T cells. In contrast, if the B cells were infected, the antigen 
would be presented in MHC class I leading to killing of these cells by CD8+ T cells 29. 
 
CD8+CD28+ and CD8+CD28− T cells 
 
CD8+ T cells can be subdivided into two subsets with different biological properties 
according to the surface expression of CD28. 
At birth, the great majority of T cells express CD28 (less than 1% of CD28− T cells in 
cord blood 33). Aging is characterised by a progressive exhaustion of naïve T cells involving 
both CD4 and CD8 subsets 34 which is accompanied by a progressive expansion of CD28− 
T cells, that is particularly evident in CD8+ T lymphocytes 35, 36. The CD28+ T cell 
population is predominant in young healthy individuals and expands during primary viral 
infection, whereas CD28− T cells are more common in elderly healthy individuals 37 and 
increase dramatically in human immunodeficiency virus (HIV) patients 38, 25. In these 
patients, specific cytotoxic activity is mainly mediated by CD8+CD28− T cells, while 
inhibition of HIV replication is controlled by CD8+CD28+ T cells 39. 
CD8+CD28− T cells have been characterised by oligoclonal expansions 40, 41, impaired 
proliferative responses, but preserved cytotoxicity and reduced telomeres 42. Some authors 
suggested that the CD28− subset has a longer replicative history (more rounds of cell 
division), and consistent with the loss of CD28 might have reached a state of replicative 
senescence 42. The average telomere length shortens between 50 to 100 base pairs with each 
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round of replication, and thus, telomere lengths can be used to assess the replicative history 
of cell populations. 
 
It has been proposed that CD8+CD28− T cells derive from CD8+CD28+ precursors 43, 
because the CD28 negative phenotype can be induced with in vitro stimulation of cord 
blood lymphocytes which typically contain only CD8+CD28+ T positive cells 44. BrdU 
labelling showed that CD8+CD28− T cells derive from CD8+CD28+ precursors in vitro 45. 
IL-4 was able to prevent, but not reverse, the switch in CD28 expression in one study 43, 
but in another study, treatment of CD8+ T cells with IL-4 decreased the levels of both 
CD28 surface expression and message and increased CD8 expression 46.   
Signalling through CD28 is the major co-stimulatory signal for activation of naïve T cells. 
Its interaction with CD80/CD86 expressed on B cells, macrophages, and dendritic cells 
stimulates IL-2 mRNA production 47, and stabilises IL-2 mRNA, thereby enabling T 
lymphocytes to proliferate in response to antigen. It also inhibits T cell receptor-induced 
apoptosis during primary T cell responses 48, 49. Once established, the proliferative response 
appears to be less dependent on CD28 co-stimulation, since exogenous growth factors 
such as IL-2 can restore mitotic progression. Normally, most CD8+ T cells do not produce 
enough IL-2 to support their own expansion 43. 
Freshly-isolated peripheral blood CD8+CD28− T cells are enriched for large and granular 
lymphocytes as assessed by flow cytometry 33, 50, and have a limited Vβ repertoire 51. This 
oligoclonality is common in healthy subjects as well as in pathological conditions 40. Loss of 
CD28 expression is also associated with a phenotype of antigen-experienced CD8+ T cells: 
CD57+CD11b+CD27−CD49+ with variable expression of CD45RO/RA 33, 37, 52. 
Co-expression of chronic activation antigens such as CD38 and HLA-DR can occur, 
particularly in HIV-infected patients 53, but acute activation antigens, such as, CD25, CD69 
and CD71 are not usually expressed 33, 37, 52, 54. 
When phenotypically compared with their CD28 positive counterparts, CD8+CD28− T 
cells have a higher expression of CD11b, CD29, CD57, and CD94 and lower expression of 
CD25 55. Affymetrix gene chip analysis of CD8+CD28− and CD28+ T cells from five 
different human T cell lines (TCL) showed differences in the level of expression of genes 
that encode cell surface molecules, signal transduction molecules, chemokines, cytokines, 
apoptosis-related proteins, cell growth regulators and metabolic enzymes 56. Natural killer 
(NK)-related receptors (CD16, CD56, CD57, CD85j, CD94, CD161, CD244, EB6, gl183, 
NKG2A, NKB1) were preferentially expressed on the CD28 negative subset, both in 
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healthy donors and also in melanoma patients 57. It is possible that the specific 
up-regulation of some inhibitory NK cell-related receptors on CD8+CD28− T cells can 
block their cytotoxic capacity, accounting for the inability of these cells to kill their target 
cells 58. 
In our previous work, we evaluated the expression of several phenotypic markers on 
CD3+CD8+CD28+ and CD28− subpopulations in whole blood from ten atopic and ten 
non-atopic volunteers. Although the phenotypic expression was similar in both atopic and 
non-atopic volunteers, overall the phenotypic expression in CD8+CD28+ T cells was 
different from that in CD8+CD28− T cells, as previously described by other authors 33, 37, 52. 
 
The functional response of the CD8+CD28− T cells is distinct from that of the 
CD8+CD28+ T cells. After stimulation of T cells with immobilised anti-CD3, freshly 
isolated peripheral blood CD8+CD28− T cells proliferated poorly, compared to the 
vigorous response of the CD8+CD28+ T cells 33. Increased anti-CD3 can compensate for 
the loss of co-stimulatory signal caused by reduced CD28 levels but fails to significantly 
increase the responsiveness of the CD28− population 46. This hyporesponsiveness could 
not be overcome by addition of exogenous IL-2, excluding the lack of IL-2 as the cause for 
this anergic response 33, 46. Proliferation of these cells was impaired, even when activated 
with mitogens that bypass TCR signalling 55. Similarly, T cell clones also demonstrated 
modest growth in response to stimulation with anti-CD3 plus IL-2, whereas CD8+CD28+ 
clones proliferated vigorously 33. Both CD8+CD28+ and CD28− T cell lines were 
observed to expand when cultured in the presence of IL-2, IL-7 or IL-15, and survived 
without significant expansion in the presence of IL-4, suggesting that proliferation might 
be important in inducing the loss of CD28 59. The reduction in proliferation might be due 
to increased RNA and protein levels of the cyclin dependent kinase inhibitor p16, as 
described by Scheuring et al. in CD8+CD28− T cells from aged adults 55. 
 
Overall, CD8+CD28− T cells are a heterogeneous subset that contains both memory and 
effector cells 60. The most established view considers CD8+CD28− T cells as terminally 
differentiated or end stage/senescent cytotoxic T cells 45, 52, although these cells were first 
described as suppressors of B and T cell function. Interestingly enough, in a number of 
situations, ranging from chronic inflammatory conditions 61 and infectious diseases 53, 62 to 
aging 52, 63, immunodeficiency 64, iron overload 65 and heavy alcohol intake 66, an increase in 
the percentages of CD8+ T cells lacking CD28 expression was found. It is currently not 
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known whether this increase in CD8+CD28− T cells is a cause for the pathology or an 
immunological response to it 50, but this association with disease suggests that they are an 
effector population.  
 
Suppressor CD8+ T cells 
 
A central finding from experimental models and human studies shows that allergic diseases 
are due to an aberrant immune response mediated through Th2 cells, characterised by a 
specific cytokine pattern. To avoid chronic cell activation and inflammation against 
non-pathogenic antigens, and control harmful T cell responses, the immune system has 
evolved a variety of regulatory mechanisms mediated by distinct T cell subsets. The 
regulation mediated by these suppressor subsets is superimposed on intrinsic regulatory 
mechanisms (such as deletion and anergy). The cellular basis of suppression was initially 
proposed in the early 1970s by Gershon and Kondo, who demonstrated that spleen cells 
from mice tolerant to sheep red blood cells could transfer the unresponsive state to naïve 
syngeneic mice 67. However, for many years, their existence was questioned until animal 
model studies of multiple sclerosis demonstrated a role for suppressor cells in protection 
against disease recurrence and exacerbation (for review see 68).  
Although, in the beginning, suppressor activity was restricted to the CD8+ T cell subset, 
nowadays the most extensively characterised population of regulatory/suppressor cells is 
that of natural CD4+CD25+ T regulatory (Treg) cells. These cells suppress immune 
responses via cell-to-cell interactions and/or the production of IL-10 and TGF-β.  
Three major subsets of CD8+ T suppressor (Ts) cells have been identified. The first type 
acts in an antigen-dependent manner via the transfer of inhibitory signals to APC by direct 
cell-to-cell contact 69, 70, 71. The second type does not require antigen recognition and acts via 
cytokine secretion 72. The third type is antigen-specific but acts through IL-10 secretion 73. 
Several studies have shown that Ts cells can act in inflammation models in chronic 






Figure 1 – Schematic representation of the mode of action of different suppressor T cells. 
From left to right: type1, type 2, and type 3 CD8+ T suppressor cells.  
(Adapted from Filaci and Suciu-Foca, 2002) 
 
Type 1 Ts are represented by CD8+CD28− T cells which inhibit allo-antigen, xeno-antigen 
and nominal antigen-specific CD4+ T cell responses. Type 1 CD8+CD28− Ts cells can be 
generated in vitro by multiple rounds of stimulation of peripheral blood mononuclear cells 
(PBMC) with allogeneic 69, xenogeneic 70 or autologous (antigen-pulsed) APC 71. These Ts 
cell lines express specific molecular markers related to natural CD4+CD25+ regulatory T 
cells, namely FOXP3 56, 74, have a limited Vβ usage 51, 70,  and are MHC-class-I-restricted 69. 
Unprimed CD8+CD28− T cells from fresh peripheral blood, which have no regulatory 
activity, do not express FOXP3, GITR, OX40, CD25, CD62L or 4-1BB 56. Inhibition of 
Th cell proliferation is not caused by killing either the APC or the Th cell, nor is the 
suppressor effect mediated by the production of cytokines. Instead, it requires direct 
interactions between the suppressor cell and the APC used for priming 69, 70, 75. The 
consequence of this interaction is the inhibition of the CD40-mediated up-regulation of 
other costimulatory molecules (CD80 and CD86) 69, 76 and the up-regulation of expression 
of the immunoglobulin-like transcript (ILT)3 and ILT4 on the surface of the APC 77, 78. The 
suppressed APC are rendered unable to induce and sustain the full programme of CD4+ 
Th cell activation due to the inhibition of the NFкB activation and transcription of 
costimulatory molecules in the APC 76, 78. Of note is the fact that Ts have a low 
proliferating rate at first but reach a sizable population upon repeated stimulation with 
antigen 79. Type 1 Ts can also be generated in vitro by allo-stimulation of PBMC from the 
peripheral blood of baboons or ACI rats. These Ts suppressed the proliferative response of 
CD4+ T cells from the same T cell line to allogeneic APC in a dose-dependent manner 80. 
Non-antigen-specific Ts, or Type 2 Ts, as well as Type 1 Ts are phenotypically 
characterised by the lack of expression of the CD28 costimulatory molecule. Type 2 Ts can 
be generated in vitro from purified circulating CD8+CD28− lymphocytes incubated for 1 
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week with IL-2 and IL-10 72. These Ts inhibit the proliferative response of T cells 
stimulated with specific antigens, anti-CD3 monoclonal antibodies or mitogens in a 
non-antigen specific way. They also seem to suppress the lysis mediated by cytotoxic cells 
72. The suppressor effect is mediated by the secretion of soluble factors, namely IFN-γ, 
IL-6 and IL-10, without direct interaction with APC 72, 81. They have a phenotype 
(CD45RA+CD27−CCR7−) and TCR repertoire suggesting that they are pre-activated and 
expanded clones 72 (for review see 82). Type 2 Ts seem to be involved in the pathogenic 
mechanisms of diseases, since failure to generate non-antigen-specific Ts is associated with 
relapse in patients with multiple sclerosis and systemic lupus erythematosus 81, 83, and in 
HIV- or hepatitis C virus (HCV)-infected patients 84.  These findings may reflect two 
opposite conditions: the physical elimination of CD8+ Ts cell precursors or the 
compartmentalization of these cells in tissues. In fact, in autoimmune thyroiditis and 
cancer, type 2 Ts were found to infiltrate affected organs leading to different outcomes: a 
protective function in thyroiditis and a pathogenic role in cancer 84, 85. 
 
A third Ts subpopulation was also identified. These cells are generated by stimulating 
purified, naïve CD8+ T lymphocytes with plasmacytoid dendritic cells (DC2). Their 
generation depends on antigen presentation and secretion of IL-10 by DC2. DC2 primed 
CD8+ T cells develop anergy to further stimulation with the same antigen and start 
secreting IL-10 themselves. These DC2 cells induce a population of CD8+ regulatory T 
cells that are anergic, non-cytolitic and capable of inhibiting primary T cell responses 
through the production of IL-10. Their inhibitory activity affects naïve but not 
pre-activated CD8+ T cells and is directly mediated by IL-10. IL-10 producing CD8+ T 
suppressor cells are directly induced via antigen presentation by DC2 and require 
antigen-specific re-stimulation to deliver their immunosuppression through the production 
of IL-10 73.  
 
CD8+ T suppressor cells may be involved in the pathogenic processes of chronic 
inflammatory diseases with immunological involvement, either due to an impairment of 
their function (autoimmune diseases) or due to an unregulated function (tumours).  The 
presence of Type 1 suppressor T cells has been associated with the absence of acute 
rejection in transplanted patients 86, 87 and is responsible for immunosuppression in animal 
models of transplantation 88. The failure to generate Type 2 Ts has been associated with 
relapse or disease progression in autoimmune diseases 81, 83, but in other settings (tumours), 
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it is the presence of these cells that allows the disease to go unchecked 82, 84. However, a 
great deal of uncertainty remains about differentiation factors, antigen specificity, and 




1.3. CD8+ T Cells in Allergy 
 
Animal models of allergy 
 
CD8+ T cells which are pivotal in tumour cell killing and protection during viral infection 
through secretion of IFN-γ and cytolytic factors have been considered to be much less 
important or even negative regulators of the development of allergic inflammation. 
A number of animal studies reported conflicting effects of CD8+ T cells in allergic airway 
disease. 
In a high IgE-responder rat model of asthma (Brown Norway rat), the depletion of CD8+ 
T cells with the monoclonal antibody (mAb) OX8 (a mouse anti-rat anti-CD8α monoclonal 
cytotoxic antibody) enhanced allergen-induced airway hyperresponsiveness (AHR) and 
eosinophil numbers in bronchoalveolar lavage (BAL) fluid. There was also a reduction in 
gene expression of Th1 cytokines in the lungs (IL-2 and IFN-γ), while the levels of IL-4 
and IL-5 remained unchanged 89.  
Using the same approach in a low IgE-responder rat (Sprague-Dawley rat), Olivenstein et 
al. observed an increased magnitude of the late airway response to inhaled allergen. This 
was accompanied by a significant increase in antigen-specific IgE and airway inflammation 
characterised by an influx of total leucocytes, macrophages, neutrophils and lymphocytes 
into the airway lumen 90.  
In an attempt to clarify the role of CD8+ T cells in the regulation of IgE and CD4+ T cell 
responses to ovalbumin (OVA), Holmes and co-workers not only depleted but also 
reconstituted sensitised rats with purified CD8+ T cells. Depletion of CD8+ T cells in vivo 
was time-dependent: depletion, 7 days after immunisation, failed to enhance IgE 
production, while depletion on days 12-18 greatly enhanced it. Reconstitution of 
CD8-depleted rats on day 12 with purified CD8+ T cells completely inhibited the IgE 
response. This effect was antigen-specific since CD8+ T cells from OVA-primed animals 
had little effect on the IgE response of bovine serum albumin immunised rats 91.  
The mechanism of this IgE regulation by CD8+ T cells was further investigated in 
wild-type and in IL-12 and IFN-γ knock-out mice. Contrary to common knowledge, the 
authors concluded that IFN-γ was required for inhibition, but had an origin other than the 
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CD8+ T cell (indirect suppression). The immunoregulatory potential of the CD8+ T cells 
was dependent on their ability to stimulate IL-12 production by the APC, leading to the 
activation of Th1 cells. In turn, the generation of OVA-specific Th1 cells inhibited 
Th2-dependent IgE class switching via production of IFN-γ 92. Surprisingly, both Tc1 and 
Tc2 cells promoted Th1 cell development and inhibited the generation of Th2 cells 92. 
Finally, Yang et al. examined the cellular basis for the poor IgE production in SJL/J mice 
upon OVA immunisation. The authors found that increased IFN-γ production by CD8+ T 
cells was responsible for their failure to make IgE 93.  
 
However, other studies suggested that CD8+ T cells are important contributors and might 
be necessary for AHR and eosinophilic airway inflammation. 
In fact, Euthymic Hooded Lister rats depleted of CD8+ cells by repeated injection of OX8 
mAb did not mount a greater IgE response when immunised with antigen alone, or antigen 
plus ricin, suggesting that CD8+ in this setting might have a “helper” function 94. 
Moreover, CD8−/− mice develop significantly lower AHR and airway inflammation 
compared with wild type mice after sensitisation and challenge with OVA. Reconstitution 
of the CD8−/− mice with magnetically isolated, OVA-primed CD8+ T cells fully restored 
the development of AHR and lung inflammation to levels comparable to those seen in wild 
type mice 95, 96. In another murine OVA model of asthma, if CD8+ T cells were removed 
prior to sensitisation, a significant decrease in AHR was observed. This was correlated with 
a decrease in the levels of IL-5 and eosinophil numbers in the lungs of these mice 97. 
Schaller et al. investigated CD8+ T cell responses in a murine cockroach antigen (CRA) 
model of asthma. Their results showed that depletion of CD8+ T cells after allergen 
sensitisation to CRA significantly reduced airway hyperreactivity, airway eosinophilia and 
pulmonary type 2 cytokine levels. CD8+ T cells from CRA-sensitised mice produced type 2 
cytokines IL-4, IL-5, and IL-13 upon antigen challenge, and the transfer of these cells into 
naïve mice caused airway hyperreactivity when exposed to CRA. This transferred airway 
response was dependent both on IL-4 and IL-13 98. The author’s data further suggests that 
both CD4+ and CD8+ T cells can mediate an airway response, and that when both cells 
are transferred into naïve mice from CRA-sensitised mice, the airway response is much 
greater than when one population alone is transferred 98. 
 
Direct comparison between these studies is difficult because of the different protocols 
used: different species (rat vs. mice) and strain models, differences in recipient status at the 
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time of reconstitution (naïve/sensitised), different routes of sensitisation, different 
adjuvants; all these factors can play a role in the final effect. In addition, different 
subpopulations of CD8+ T cells do exist and can be at different functional stages of 
differentiation, some of which suppress and others enhance Th2-responses. It is 
noteworthy that it is being recognised that the cell and cytokine requirements during the 
initiation/sensitisation phase differ considerably from those that might be necessary during 
the challenge/maintenance/progression phase 99, 100. CD8+ T cells could play an important 
inhibitory role early on during the sensitisation phase on the allergen-induced response, but 
once the systemic sensitisation is established, CD8+ T cells may play a bystander or 
pro-inflammatory role 101. 
 
Human allergic disease 
 
As we have seen, CD8+ T cells are important immunoregulatory cells in some animal 
models of allergic disease, but proinflammatory in others. Dichotomous findings with 
respect to CD8+ cells led to attempts to further characterise CD8+ cells in human allergic 
immune responses. 
 
According to the “Th2 hypothesis for asthma” asthmatic subjects have a relative deficiency 
in IFN-γ production or an imbalance towards type 2 cytokine production 102. Because Th1 
cells antagonise Th2 cell functions, it was proposed that immune deviation towards a Th1 
pattern could protect against asthma. It was then suggested that CD8+ T cells might play a 
protective role in the pathogenesis of allergic inflammation via their ability to produce 
IFN-γ. This IFN-γ could inhibit the development of Th2 cells directly and inhibit IgE 
synthesis by B cells. 
 
Several authors investigated the secretion of IFN-γ by CD8+ T cells from patients with 
allergic asthma and healthy controls. 
One study showed that PMA (phorbol myristate acetate) and calcium-ionophore-induced 
IFN-γ secretion by isolated CD8+ T cells in patients with asthma was lower than that of 
healthy controls, but was significantly increased after stimulation with anti-CD3 antibodies 
103. Using a bronchial explant system without any stimulation, the mRNA expression for 
INF-γ was higher in cultured bronchial biopsies from control subjects compared with that 
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from asthmatic subjects 104. Several other studies observed an increased rather than a 
decreased synthesis of IFN-γ by CD8+ T cells in allergic patients, when compared with 
healthy controls. This increased IFN-γ production was observed when imunomagnetically 
isolated CD8+ T cells from the peripheral blood were stimulated with Der p 1 105 or total 
PBMC were stimulated with PMA and ionomycin 31, 106. Interestingly enough, the number 
of IFN-γ-producing CD8+ T cells correlated with asthma severity, bronchial 
hyperresponsiveness and blood eosinophilia in a group of atopic asthmatic patients 106.  
 
In allergic patients, there is evidence that Tc2 CD8+ T cells are present both at the site of 
allergic inflammation and in the peripheral blood. Using double immunohistochemistry and 
in situ hybridisation, Ying et al. showed that in atopic and non-atopic asthma 70% of IL-4 
and IL-5 mRNA signals co-localized to CD3+ T cells, the majority of which were CD4+ 
although CD8+ T cells also expressed IL-4 and IL-5 mRNA 107.  Similar results were 
obtained for CD8+ T cell from the peripheral blood of asthmatic children 108. 
Both activated CD4+ and CD8+ T cells were shown to encode mRNA for IL-4 and IL-5 
in atopic and non-atopic asthmatic adults 107 and children 108. It is of note that, after 
treatment with inhaled corticosteroids, there was a clinical improvement in the asthmatic 
patients associated with reduced T cell activation and cytokine mRNA expression 108.   
CD8+ T cells isolated from the peripheral blood of patients with mild atopic asthma 
contain higher levels of intracellular IL-4 than those from healthy non-atopic subjects. 
Additional ex vivo stimulation with Concanavalin A does not enhance IL-4 production, 
suggesting that in asthma CD8+ T cells are conditioned in vivo to produce greater amounts 
of this Th2-type cytokine 109. 
The Th2 cytokine medium found at the asthmatic lung can transform CD8+ cytotoxic T 
cells into non-cytotoxic IL-5 producing cells in vivo. This IL-4 dependent switch to CD8+ 
T cells that secrete IL-5 is thought not only to promote eosinophilia, but also to lead to 
impaired viral clearance owing to a reduction in IFN-γ production 110. 
However, CD8+ T cells are not the principal source of lung IL-5; Till et al. even doubt that 
they are relevant. In freshly isolated PBMC, IL-5 but not IFN-γ production by T cells was 
elevated in atopic patients with asthma and in atopic patients with rhinitis in response to 
challenge with dust-mite allergen. This IL-5 production correlated with bronchial 
hyperreactivity and was abrogated by depletion of CD4+, but not CD8+ T cells111. 
Finally, it was suggested that CD8+ T cells can contribute to the pathology of asthma 
death due to an enhancement of the pre-existing airways inflammation in response to viral 
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infection 112, 113. In fact CD8+ T cells are more sequestrated than CD4+ T cells in the 
airway during an acute asthma attack 114. 
 
Recently, Seneviratne et al. showed that Dermatophagoides pteronyssinus (Der p) 1-specific 
CD8+ T cells exist in humans and that it is possible to map the precise class I epitopes and 
characterise patterns of cytokine production. The authors’ data demonstrate that as in the 
case of allergen-specific IgE, allergen-specific CD8+ T cells do exist, are restricted to the 
atopic group, and have impairment in IL-10 production 16. This is an unexpected finding as 
it proves that CD8+ T cells are able to respond to exogenous antigens and associates 
diminished production of a regulatory cytokine, IL-10, to disease severity. 
 
In summary, CD8+ T cells do not exhibit a fixed phenotype but can differentiate into 
functionally distinct subsets that might suppress, enhance, or divert immunopathologic 
processes in response to the environment. 
 
In order to contextualize our cellular findings, we decided to initially characterise our study 
populations (patients with allergic rhinitis and patients with bronchial asthma) from an 






Many authors believe that atopy and allergic diseases are the result of inadequate or 
impaired inhibition of allergen-specific T helper-type responses by regulatory T cells (Treg) 
115, or even a consequence of decreased frequencies of those cells in atopic individuals 116. 
In other disease settings (transplantation, autoimmunity), CD8+ T cells were proven to 
have a suppressor function and contribute to the maintenance of peripheral tolerance. 
Papers on the mechanisms of asthma and allergic inflammation were unable to assign a 
single function for CD8+ T cells in these settings. This fact can be due to the existence of 
more than one CD8+ subpopulation with relevance for the development and regulation of 
immediate hypersensitivity. Bearing in mind all the research on the subject, it was our firm 
belief that the present study could enhance the knowledge and shed some light on the 
functional properties, rather cytotoxic or suppressor, of CD8+ T cells in allergic diseases. 




1. Peripheral blood CD8+ T cells inhibit proliferation and cytokine synthesis in 
CD4+ effector T cells induced by exposure to allergen. 
2. Sputum CD8+ T cells from asthmatic patients are activated. 
3. CD8+ T cell activation in sputum from asthmatic patients correlates with disease 





AIMS OF THE THESIS 
 
Despite the growing interest in T cells observed in the last few years in various fields, 
studies addressing the function of CD8+ T cells in allergy have been scarce. The main aim 
of this thesis was to study the role played by CD8+ T cells in the development of allergic 




1. To assess allergen-specific proliferation and cytokine synthesis of CD8+ T cells. 
2. To evaluate the suppressor function of CD8+ cells on antigen-specific responses. 
3. To assess the presence of CD8+ T cells at the target organ and their activation 
status. 
4. To assess the correlation between the expression of the activation markers on 
CD8+ T cells and asthma severity and control. 
5. To demographically characterise samples of patients used for the cellular studies. 
 
 








2. Background on the Methods 
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Peripheral blood offers an indirect way to analyse inflammation at the target-organ. It has 
the advantage of being an easy access source and generator of minimal discomfort to the 
volunteers. Prior to using freshly drawn peripheral blood, we tried an alternative method of 





Induced sputum offers a more accurate assessment of airway inflammation and cellular 
infiltration than other non-invasive techniques that analyse markers in peripheral blood 
such as blood eosinophil count, serum ECP or in exhaled air, such as nitric oxide.  
Although sputum is derived mainly from the central, more proximal airways, and BAL fluid 
and bronchial washings (BW) samples from more peripheral airways and the alveolar 
compartment, the cellular composition of sputum correlates well with that found both in 
BW and BAL fluid and, to a lesser extent, with the cellular influx seen in bronchial 
biopsies. In addition, sputum induction is less invasive than BAL or bronchial biopsies, and 
has been shown to be safe even in severe asthma.  
Sputum is composed of fluid and cellular components, including macrophages, bronchial 
epithelial cells and inflammatory cells. When it is expectorated, it becomes mixed with 
saliva composed mainly of fluid, squamous epithelial cells, and oropharyngeal bacteria. 
The method of sputum induction has many advantages, but it has also a few major 
drawbacks. These include the need for qualified technicians and the time consuming nature 
of the technique. The total time required for induction, processing and performing a 
differential cell count will amount to approximately 100min. The need to process sputum 
within two hours after induction restricts the use of the method. 
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Finally, a very important aspect of sputum obtained by standardised techniques is that it 
can yield sufficient amounts of cells that can be analysed using different techniques. Above 
all, it is now possible to use flow cytometry for the analysis of cellular subtypes and cellular 
activation. 
 
2.2. Cell Isolation 
 
Immunomagnetic cell sorting 
 
The ability to fractionate lymphocytes on the basis of surface phenotype has been a major 
technical advance in the study of the functional diversity of these cells. Many of the 
methods currently in use exploit antibody specificity to separate cells of one type from a 
mixed population. Cell lysis with antibody and complement is useful only for cell 
elimination. Separation by affinity column chromatography, lymphocyte panning or 
fluorescence-activated cell sorting offers the advantage of positive or negative selection by 
allowing the recovery of both enriched and depleted cell populations.  
In recent years, several companies have been working on methods for increasing the purity 
and recovery of rare cell types. Pre-enrichment steps usually start with “debulking” of the 
sample based on differences in cell density or cell size, followed by a more selective 
method that can yield a higher number of purified cells. A balance must be maintained 
during the process as higher purity can result in low yield. 
Differences in size and density have led to the use of density gradients for the removal of 
mature red blood cells from haematopoietic cell suspensions. In the present study, we used 
Lymphoprep (Axis-Shield). For further purification of our cell fraction, we used magnetic 
cell sorting as available from Miltenyi Biotec (MACS system). 
In magnetic cell sorting, cells are incubated with an antibody (or an antibody mixture) 
specific for a particular cell that is covalently linked to a magnetic bead. After magnetic 
labelling, cells are passed through a separation column which is placed in a magnetic field; 
unbound cells flow through the magnetic phase while the bead-bound cells are retained in 
the column. Once the column is removed from the magnetic field, the bead-bound cells are 
eluted.  
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Cells can also be labelled indirectly by first being incubated with a primary unconjugated or 
fluorochrome-conjugated antibody followed by magnetic labelling by using 
anti-immunoglobulin or anti-fluorochorme MicroBeads. Indirect labelling is compatible 
with simultaneous fluorescent staining for subsequent flow cytometric or microscopic 
analysis. Indirect labelling is useful to amplify the magnetic label, which may be important 
if dimly expressed markers are used for magnetic separation.  
There are two main strategies for isolating cells: positive selection or enrichment and 
negative selection or depletion. With positive selection, the target cells are labelled with the 
magnetic beads and are retained in the column. The binding of MACS MicroBeads to the 
cell surface will rarely affect its function or viability. By positively selecting we take 
advantage of the speed and specificity of a monoclonal antibody and, in most situations, 
this strategy saves time and money. If a positive selection strategy is not feasible (no 
available antibody or if cell activation may be induced by the existing antibody) then a 
depletion strategy should be used. The method of choice will depend on the antibodies 
available and the subsequent use of the cells. 
MicroBeads are an average 50nm in diameter (which avoids mechanical stress) and are 
made of biodegradable iron oxide and polysaccharide. Removal of the bead is therefore not 
necessary for further analysis and the cells retain their function. The beads form a colloidal 
suspension, do not sediment or aggregate in magnetic fields,  and can be used for positive 
selection of cells with frequencies as low as 10−8. As only a certain percentage of the cell 
epitopes are bound by antibody-bead complexes, it is possible to use antibodies with the 
same specificity for magnetic and fluorescent labelling (this general rule cannot be applied 
to dimly expressed antigens). 
MACS technology can separate 105 to 1011 cells using the same technique with different 
size columns with a typical purity and recovery greater than 90   percent. Cells eluted from 
the column are ready for cell culture, flow cytometry, PCR (polimerase chain reaction), 
fluorescent microscopy or FISH (fluorescence in situ hybridisation). 
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Flow cytometry is a technique which evaluates cellular parameters, either morphological or 
phenotypical at a single cell level. Cells under study are incubated with monoclonal 
antibodies conjugated with fluorochromes that specifically bind cellular components. 
The system measures biophysical properties of the cells that are related to biochemical and 
biological properties. Without the use of fluorochromes it is possible to determine size (by 
forward scatter) and complexity (by side scatter) of cells (or other particles) under study. 
The fluorochromes are excited by the laser beam and emit light in longer wavelengths. It is 
this emitted light that is captured by the detectors and transformed into digital signals that 
can be stored and analysed. 
The relative amount of a particular molecule in different cell subpopulations can be studied 
by determining the amount of fluorescence that is emitted. 
The majority of the conjugated monoclonal antibodies are specific for components on the 
cellular surface; however, it is possible to mark intracellular components by permeabilizing 
the cells temporarily, which permits the entry of the antibody. It is also possible to use 
fluorescent probes that indicate ionic cytoplasmic concentrations and oxidation-reduction 
potential.  
This method evaluates different parameters (number-dependent on cytometer) at a single 
cell level and it is possible to study the heterogeneity of a sample and the presence of 
contaminants or rare populations. It is a very fast technique with measurements being 
made at a rate of 1000 events per second on average. There are simple protocols for whole 
blood which eliminate the need for previous cell isolation. The sensitivity is high as well as 
the reproducibility, but laser usage and compensation settings should be carefully 
monitored as they might influence these parameters. As a setback, the equipment is rather 
expensive and all the procedures must be performed by trained personnel. 
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2.4. Cytokine Synthesis 
 
Cytometric Bead Array 
 
The Cytometric Bead Array (CBA) by Becton Dickinson employs a series of particles with 
distinct fluorescence intensities to simultaneously detect multiple soluble analytes in a 
particle-based immunoassay. Each bead provides a capture surface for a specific protein 
and is analogous to an individual coated well in an ELISA plate. The bead mixture is in 
suspension to allow for the detection of multiple analytes in a small volume sample. The 
CBA Human Th1/Th2 kit we used can quantitatively measure IL-2, IL-4, IL-5, IL-10, 
TNF-α, and IFN-γ protein levels in a single sample. This kit performance is optimised for 
analysis in tissue culture supernatants, plasma and serum samples. 
CBA provides several advantages when compared with conventional ELISA: the required 
sample volume is approximately one-sixth of the quantity necessary for conventional 
ELISA assays due to detection of six analytes in a single sample; a single set of diluted 
standards is used to generate standard curves for all 6 analytes; the experiment takes less 
time and is cheaper when compared with six conventional ELISA tests. However, due to 
the complexity and kinetics of a multi-analyte assay, sensitivity is lower than in some 
ELISA tests (microELISA). 
 
2.5. T Cell Proliferation 
 
Tritiated Thymidine ([3H]-thymidine) Incorporation 
 
The measurement of tritiated thymidine ([3H]-thymidine) incorporation is one of the most 
familiar and widely used methods for quantifying cell proliferation. Cells incorporate the 
labelled DNA precursor into newly synthesised DNA, such that the amount of the 
incorporation, measured by liquid scintillation counting, is a relative measure of cellular 
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proliferation. However, this technique is time-consuming and labour intensive, and exposes 
the researcher to scintillation fluid and tritium, both of which are toxic. 
 
CFSE Fluorescence Loss 
 
T cells can be labelled with chemically reactive lypophilic fluorescent esters, which enter 
cells and form covalent bonds with cytoplasmic proteins and then cannot leave the cells. 
These dyes become markers of T cells. Every time a T cell divides, its dye content is 
halved. By analysing their dye content in a flow cytometer, it is possible to estimate the 
number of doubling processes each T cell has gone through. 
Carboxy-fluorescein diacetate succinimidyl ester (CFSE or CFDA-SE) is a fluorescein 
derivative which is cell permeant and non-fluorescent. After entering the cell, cellular 
esterases cleave the acetate groups, rendering the molecule fluorescent and cell 
impermeant. The succinimidyl ester binds to free amines resulting in long lived fluorescent 
adducts that are equally diluted into daughter cells after mitosis. After each division, halving 
of CFSE fluorescence is observed. Fluorochromes compatible with fluorescein can be used 
to assess other cellular properties. 
When combined with staining with fluorescent-labelled monoclonal antibodies, CFSE 
fluorescence loss has advantages over [3H]-thymidine incorporation in the assessment of T 
cells proliferation, as it allows simultaneous identification of the cells, the number of 


















3.1. Demographic, Laboratory and Clinical 
Characterisation of Adult Asthmatic Patients 




Asthma is a heterogeneous chronic inflammatory condition characterised by reversible 
airway obstruction and hyperresponsiveness associated with underlying bronchial 
inflammation and structural changes. It represents an increasing health problem and is a 
huge burden on patients, their families and society. The aim of the present study was to 
characterise the adult asthmatic population attending a Hospital Allergy Clinic between the 
years of 2003 and 2006. 
Methods 
Clinical files from the Allergy Outpatient Clinic of the Cova da Beira Hospital were 
sequentially studied. The total population analysed included 335 female and 130 male 
asthmatic patients. Bronchial asthma was characterised by clinical history, skin prick testing 
to aeroallergens, determination of total and specific IgE and lung function testing, and 
classified according to international guidelines. 
Results 
Of the patients studied, 70% had allergic asthma and 30% had non-allergic asthma. When 
compared to allergic asthma, non-allergic asthma was more frequently associated with older 
age, perennial symptoms and female gender. More allergic than non-allergic asthma 
patients also had rhinitis and the reverse was true regarding drug allergy and oesophageal 
reflux. Grass pollen and mites were the major sensitisers for allergic asthmatic patients. The 
sensitisation profile was significantly different between urban- and rural-based asthmatic 






In this population, rhinitis was more frequently associated with allergic than with 
non-allergic asthma. The two types of asthma did not differ in clinical severity or changes 
in lung function. Sensitisation profiles were different between the urban and rural patients. 
 
3.1.2. Introduction 
Asthma is a chronic, complex, obstructive lung disease characterised by acute symptomatic 
episodes of varying bronchial constriction that occur in response to allergens or other 
triggers such as viral infections and exercise.  Asthma is a major cause for work and school 
absenteeism with repercussions on quality of life and high socio-economic impact 117, 118. 
The majority of bronchial asthma cases generally start in childhood or adolescence in 
individuals responding to common aeroallergens and are mediated by immunologic 
mechanisms (allergic asthma). Other patients develop asthma later in life, often as a 
consequence of viral respiratory infections and without history or symptoms characteristic 
of atopy or allergic diseases (non-allergic asthma) 3. Most patients with allergic asthma have 
other concurrent allergic diseases, namely rhinitis, which should be treated in order to 
improve asthma symptoms 119. In addition to phenotypes, asthma can also be classified 
according to its severity ranging from intermittent, mild transient episodes to severe, 
chronic, life-threatening bronchial obstruction 120, 121. 
Asthma is a worldwide disease that has been recognised for centuries, but prevalence 
figures vary, in part, because of differences in definition and methods of case finding. In 
order to know the prevalence of allergic disease worldwide, the International Study of Asthma 
and Allergies in Childhood (ISAAC) has been developing a research for the last 15 years, 
involving more than 50 countries. Portuguese data estimate a prevalence of actual asthma 
of 12.9% in 6-7 year olds and of 21.8% in 13-14 year olds 122, 123. The data from the 
European Community Respiratory Health Survey (ECRHS), which involved surveys of asthma 
and allergic rhinitis prevalence in adults aged 20-44 years, estimated that 5% of the 
Portuguese adult population has bronchial asthma 124. However, in spite of these aspects, 
studies describing the features of Portuguese asthma patients are lacking in the literature.  
To increase the current knowledge about asthma patients in Portugal we aimed at 
characterising the adult asthmatic population attending the Allergy Clinic of the Cova da 







 3.1.3. Materials and Methods 
Clinical files from patients attending the Allergy Outpatient Clinic of the Cova da Beira 
Hospital between 2003 and 2006 were sequentially studied. 
The study protocol was approved by the Hospital Ethics Committee. 
The diagnosis of bronchial asthma was based upon clinical history, physical examination, 
pulmonary function tests, and response to inhaled β-adrenergic agents according to 
international guidelines 120. Skin prick testing to aeroallergens and determination of total 
and specific IgE were also performed on the asthmatic patients. 
Assessment of severity was based on daytime symptoms, night-time symptoms, frequency 
and intensity of attacks, impact on daily activities, asthma treatment used and predicted 
percentages of forced expiratory volume in one second (FEV1) and peak expiratory flow 
(PEF). All patients were also examined by anterior rhinoscopy and filled in a questionnaire 
regarding nasal symptoms. Smoking habits were recorded as pack-years. 
The designation of “non-allergic” was applied when the history, skin prick testing, and 
serum specific IgE measurements included in the allergy examination were all negative. 
All the data were analysed using non-parametric tests. Results are expressed as medians and 
range. Wilcoxon signed rank test was used for comparisons within groups and Mann 
Whitney U test, chi-square test and Kruskal-Wallis test were used for comparisons between 
groups. The association of various clinical parameters was analysed using the Spearman 
rank correlation test. A p value of less than 0.05 was considered significant. All analyses 




The total population analysed included 1078 clinical files. From those, we excluded all 
patients under 18 years and patients not currently living in the area. In addition, 25 patients 
were excluded because of discordance between skin prick tests and specific IgE tests. 
Four hundred and sixty five clinical files, from adult Caucasian asthmatic patients (335 





Allergic versus non-allergic asthmatic patients 
Seventy percent (327) of the asthmatic patients had a diagnosis of allergic asthma and thirty 
percent had non-allergic asthma. Demographically, there were significant differences 
between the two groups. There were more women among non-allergic asthmatic patients 
than among allergic asthmatic patients, with female: male ratios of 5.3 and 2.0, respectively 
(p<0.001). In addition, allergic patients were significantly younger than non-allergic 
asthmatic patients (median age 35 (18-85) vs. 51 (18-84) years, p<0.001). Smoking habits 
were not different between allergic and non-allergic patients. 
Bronchial asthma was classified according to the old practice that divided it into seasonal 
and perennial. In this regard, we observed that seasonal symptoms were more common in 
allergic than in non-allergic patients (40.0% versus 18.2%, χ2= 8.992, p= 0.003).  
Patients were divided into three age groups and severity was assessed according to the 
Global Initiative for Asthma guidelines 121. With increasing age, there was an increase in the 
severity of asthma both in allergic and non-allergic asthmatic patients (χ2= 12.305 for 
allergic and 12.937 for non-allergic, p=0.015 and 0.012 respectively). However, there were 
no differences in terms of severity between allergic and non-allergic asthmatic patients 
(p>0.05) (Figure 2). 
 
 
Figure 2 – Relationship between severity of asthma and age in allergic asthmatic (Panel A) and 
non-allergic asthmatic (Panel B) patients.  
Patients were grouped into three age groups and severity was assessed according to GINA 
guidelines. Severity increased with age but was not statistically different between the two groups. 
 
Some patients with asthma have chronic cough as their main, if not only, symptom, and 
others have physical activity as the single cause for asthma. More non-allergic than allergic 
asthmatic patients had cough-variant asthma (15.2% vs. 6.4%; χ2= 9.137; p=0.003), which 
could not be attributed to differences in work problems or exposure. Exercise-induced 






Figure 3 – Prevalence of exercise-induced and cough-variant asthma in allergic and non-allergic 
asthmatic patients.  
Non-allergic asthmatic patients had a higher prevalence of cough-variant asthma compared to 
allergic asthmatic patients. 
 
Measurements of lung function provide an assessment of the severity, reversibility, and 
variability of airflow limitation, and help to confirm the diagnosis of asthma. Pulmonary 
function test data was expressed in terms of percentage of predicted values. 
Lung function testing values were not significantly different between allergic and 
non-allergic asthmatic patients (Table 1). 
 
Table 1 – Lung function testing values in allergic and non-allergic asthmatic patients. 
 
 Allergic asthma Non-allergic asthma  
% FEV1 
101.9 ± 1.1 
102.0 [51-148] 




105.8 ± 1.0 
106.5 [50-159] 




0.82 ± 0.01 
0.82 [0.46-1.1] 




92.7 ± 1.2 
92.0 [41-151] 




80.9 ± 1.9 
81.0 [15-180] 
78.4 ± 3.0 
83.0 [13-150] 
p=0.7321 
Data are represented as mean ± standard error of the mean and median and range.  
Comparisons between both groups were evaluated by the Mann-Whitney U test. 
 
Bronchial asthma is frequently associated with rhinosinusal involvement (even in 





present in our asthmatic population and observed that the great majority of the asthmatic 
patients had rhinitis and conjunctivitis. There were differences between both groups, with 
non-allergic asthmatic patients having a lower prevalence of rhinitis, but a higher 
prevalence of drug allergy and oesophageal reflux as compared to allergic asthmatic 
patients (Figure 4). 
 
Figure 4 – Main co-morbidities associated with bronchial asthma.  
Allergic asthmatic patients (light bars) had a higher prevalence of rhinitis, whereas non-allergic 
asthmatic patients (dark bars) had a higher prevalence of drug allergy and oesophageal reflux. 
 
As expected, total serum IgE was significantly higher in allergic asthmatic patients than in 
non-allergic asthmatic patients (median 205 (3-5000 IU/ml) vs. 27 (<2-653 IU/ml), 
p<0.001). There was no correlation between total IgE levels and features of allergic 
sensitisations (wheal size on the skin prick tests or specific IgE levels). 
Sensitisations in allergic asthma 
In allergic asthmatic patients, the frequency of sensitisations evaluated by skin prick testing 
was 65.5% for grass pollen, 62.9% for mites, 62.6% for cereal pollen, 49.3% for tree pollen, 





cat dander (Figure 5). The percentage of monosensitised allergic asthmatic patients was 
12%, with 6.5% of asthmatic patients being monosensitised to mites, 2.5% to grass pollen 
and 2.2% to weed pollen. There were no asthmatic patients monosensitised to cereal, dog 
dander or moulds. The frequency of sensitisation evaluated by specific IgE was slightly 
different but was directly correlated with that from skin prick tests (Table 2). 
 
Figure 5 – Cutaneous reactivity to aeroallergens in allergic asthmatic patients.  
Allergen sensitisation was evaluated by skin prick test with a battery of the most common 
aeroallergens in the local flora, as well as mites, moulds and animal dander. 
 
 
Table 2 – Sensitisation profile in the allergic asthmatic patients. 
 
Allergens 




Cat dander 101 (36.3%) 32 (15.3%) 
Cereal pollen 174 (62.6%) 110 (52.6%) 
Dog dander 83 (30%) 27 (12.9%) 
Grass pollen 182 (65.5%) 123 (58.9%) 
Mites 175 (62.9%) 123 (58.9%) 
Moulds and fungi 61 (21.9%) 4 (1.9%) 
Tree pollen 137 (49.3%) 99 (47.4%) 





The major allergen sensitisers, as evaluated by skin prick testing and specific IgE, were 
grasses (Lolium perenne, Phleum pratense, Dactylis glomerata and Poa pratensis), cereals (Secale 
cereale, Triticum sativum and Avena sativa), mites (Dermatophagoides pteronyssinus and 
Dermatophagoides farinae), trees (Olea europea and Platanus acerifolia), the weed Parietaria judaica 
and the mould Alternaria alternata. A very interesting observation was that, in spite of similar 
prevalence of these major allergens, there were significant differences in terms of the 
class/level of sensitisation as measured by wheal size and specific IgE values (Figure 6). 
There was no correlation between the wheal size of the prick tests or the pattern of allergen 
sensitisation and the severity of the disease.  
 
Figure 6 – Degree of sensitisation to aeroallergens in allergic asthmatic patients.  
The degree of sensitisation, as analysed by specific IgE levels, was different between the major 
aeroallergens. 
 
Rural versus urban asthmatic patients 
As environmental factors, such as air pollution, are thought to play a part in sensitisation, 
we then compared several features between urban and rural asthmatic patients. Our 
population included 141 urban and 182 rural allergic asthmatic patients. The samples were 
paired for age and gender. 
The sensitisation profile was significantly different between urban- and rural-based 
asthmatic patients, with more rural than urban asthmatic patients being sensitised to tree 





22.1% p<0.001, respectively). However, the level of sensitisation was similar for all the 
allergens (p>0.05 Mann Whitney U test). Furthermore, there were no differences regarding 
severity of asthma between rural and urban allergic asthmatic patients and the same was 
valid for non-allergic asthmatic patients. 
 
3.1.5. Discussion 
Asthma is a major public-health problem that is increasing in prevalence in most developed 
countries. Data regarding prevalence and sensitisation profiles in bronchial asthma are 
scarce in Portugal. Given its heterogeneous nature, it is important to thoroughly 
characterise bronchial asthma in order to improve treatment measures. 
Thirty percent of our asthmatic patients were non-allergic. This proportion is analogous to 
that found in similar studies with hospital-based recruitment 125, and is in accordance with 
the relative prevalence of non-allergic asthma, considered to vary between 10 and 30% 126.  
In the present study, we observed that non-allergic asthmatic patients were older, 
predominantly female, and had a higher prevalence of drug allergy and oesophageal reflux, 
but a lower prevalence of rhinitis than allergic asthmatic patients. A previous French study 
aiming at describing clinical similarities and differences between allergic and non-allergic 
asthmatic patients also found an association between non-allergic asthma and older age, 
and female sex. However, in contrast to this study, we did not find differences in terms of 
FEV1 values between allergic and non-allergic asthma 125. This difference may be attributed 
to different study designs, namely in terms of severity and treatment of the asthmatic 
patients included in both studies. 
Asthma and rhinitis frequently occur concomitantly, with a reported prevalence of up to 
100% in those patients with allergic asthma 127. In the ECRHS, an association between 
asthma and rhinitis was observed even in non-atopic individuals 128. In our study, there 
were significantly more allergic than non-allergic asthmatic patients with concurrent 
rhinitis. This may be due to the fact that many of the allergic asthmatic patients develop 
allergic rhinitis early in life and later develop bronchial asthma 128. The importance of 
having concurrent rhinitis is highlighted by the key concept that has emerged in recent 
years that rhinitis and asthma should be viewed as disorders of a single airway. Having co-
morbid allergic rhinitis is a marker for the presence of more-difficult-to-control asthma and 





It is possible that the prevalence of co-morbid allergic rhinitis in this retrospective study 
was underestimated, because the diagnosis of allergic rhinitis was restricted to that recorded 
in medical records. Many people with allergic rhinitis self-manage the condition with 
over-the-counter products, do not seek a physician’s help, or indeed do not recognise 
allergic rhinitis as a condition needing treatment. However, it must be borne in mind that 
all asthmatic patients included in this study were specifically asked about symptoms of 
rhinitis and anterior rhinoscopy was carried out in all of them. 
Some patients with asthma have chronic cough as their main, if not only, symptom. 
Curiously, in our study, we found significantly more non-allergic than allergic asthmatic 
patients with cough-variant asthma. This cannot be explained in terms of severity of the 
underlying asthma since there were no differences between allergic and non-allergic 
patients in this regard. It may be due to the fact that significantly more non-allergic 
asthmatic patients had gastro-oesophageal reflux. Alternatively, non-asthmatic patients may 
have a lower threshold for triggering cough reflex receptors in the bronchial mucosa. 
In the literature, non-allergic asthmatic patients characteristically have a later onset of 
symptoms with a more severe clinical course of the disease than those with allergic asthma. 
This is in clear contrast with the present study. This difference could be related to the fact 
that our patients were classified by asthma severity at the first appointment but many of 
them were not treatment-naïve at that time.  
In our population, major allergic sensitisers included the Poaceae family (grass and cereal 
pollens) and mites. This is in agreement with a previous study that analysed aeroallergen 
sensitisation in the paediatric population of Cova da Beira, and which observed a similar 
pattern of sensitisation with grasses, Olea europea, Parietaria judaica as the most representative 
sensitisers 129. The Iberian study of aeroallergen sensitisation in allergic rhinitis reported 
similar results with common polysensitisation, involving both mites and pollens 130, without 
significant differences between the coastal and inland areas.  
In the present study we provide for the first time data on the magnitude of sensitisations 
for the major allergens in Portugal. Interestingly enough, we show that there are significant 
differences in terms of the level of sensitisation as measured by specific IgE classes. In 
spite of similar prevalences within the major allergens, a particular species or family seems 
to be the main responsible agent for the symptoms, as happens with the grass pollen Lolium 
perenne, in contrast to Olea europea.  Accurate identification of the specific cause of allergic 





In terms of allergen sensitisation in urban- and rural-based asthmatic patients, we found a 
higher prevalence of tree pollen allergy in the rural context and a higher prevalence of 
sensitisation to moulds in the city. This may be due to the fact that city dwellings are more 
humid and tree pollen sources (Olea trees) are more densely present in the countryside, 
thereby locally increasing the allergen load. In contrast, in a similar study involving patients 
with allergic rhinitis in the Cova da Beira area, the prevalence of sensitisation to grasses, 
weeds and Olea europea was higher in the urban group 131. In urban areas, pollen grains can 
become coated with fuel residues and combustion products, and this binding of pollen to 
diesel exhaust particles may modulate the allergenic epitopes and increase their allergenicity 
132. Our findings, however, may be related to the relative size of sensitiser particles, as our 
study essentially included patients with bronchial asthma in contrast with the other study, 
which mainly involved patients with allergic rhinitis.  
One limitation of our study is that the study sample of adults with asthma was drawn from 
a specialised allergy practice, and may differ significantly from the general population of 
asthmatic patients, since asthmatic patients treated by specialists appear to have more 
severe asthma than those seen by general practitioners.  
In summary, in this study, rhinitis was more frequently associated with allergic than with 
non-allergic asthma, but drug allergy and oesophageal reflux were more associated with 
non-allergic asthma. In addition, the two types of asthma could not be differentiated in 
terms of severity of clinical symptoms. 
The major allergens in the area were grass pollen, cereal pollen, mites and Olea europea. 
Monosensitisation was uncommon and it mainly included mites. 
Urban- and rural-based asthmatic patients had different sensitisation profiles, but could not 
be differentiated in terms of severity of their disease. 
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3.2. Asthma is more frequently associated with 
Non-allergic than Allergic Rhinitis in Portuguese 
Patients 




The prevalence of rhinitis is increasing worldwide and is frequently associated with asthma, 
for which it is a risk factor. The aims of the study were to characterise the adult population 
with rhinitis attending the Cova da Beira Hospital Allergy Clinic, and to assess the 
relationship between rhinitis and asthma. 
Methods 
686 patients were characterised by clinical history and anterior rhinoscopy, and classified 
according to international guidelines. Atopy was determined by skin prick testing to 
aeroallergens and quantification of specific IgE. 
Results 
Seventy two percent of patients had allergic rhinitis (AR), and 28% had non-allergic rhinitis 
(NAR). NAR was more frequently associated with older age, perennial symptoms and 
female gender. NAR patients more frequently had bronchial asthma. In addition, more 
NAR than AR patients also had drug allergy, pharyngitis, sinusitis and urticaria. AR patients 
with nasal polyps more frequently had asthma. Grass pollen and mites were the major 
sensitisers for AR patients. Sensitisation profiles were not significantly different between 
urban- and rural-based AR patients. 
Conclusions 
Asthma was more frequently associated with non-allergic than with allergic rhinitis. The 





not different between the urban and rural patients, the prevalence of allergic rhinitis was 
higher in urban patients. 
 
3.2.2. Introduction 
Rhinitis is a symptomatic disorder of the nose characterised by nasal blockage/congestion, 
rhinorrhea, itching and sneezing. Subdiagnosis is frequent as the disease is often trivialised, 
despite important impairment in the quality of life, increased medical costs and decreased 
school and work productivity. 
The majority of rhinitis cases generally start in childhood or adolescence in individuals 
responding to common aeroallergens and are mediated by immunoglobulin E (IgE) 
(allergic rhinitis or AR) 133. AR is diagnosed by history and examination backed up by 
specific allergy tests 134.  
Other patients develop non-allergic forms of rhinitis, such as idiopathic rhinitis, hormonal 
rhinitis, food-induced rhinitis, or drug-induced rhinitis (non-allergic rhinitis or NAR) 135. 
NAR includes a number of heterogeneous nasal conditions, in their majority poorly 
defined in terms of their underlying mechanisms, and with multifactorial aetiology 136. 
Unlike AR, there are no specific diagnostic tests for NAR. The diagnosis is primarily made 
by excluding allergy-related features and infectious causes, as well as by assessing history of 
reactions to specific irritant/toxic triggers. In addition, the presence of nasal and blood 
eosinophilia as well as hormonal status (mainly estrogens) should be analysed. 
Furthermore, NAR can also contribute to rhinitis symptoms in atopic patients, creating a 
“mixed” phenotype 135. 
Based on the time of exposure to allergens, allergic rhinitis has been classified as seasonal 
allergic rhinitis (SAR), also known as hay fever, and perennial allergic rhinitis. SAR was 
associated with outdoor allergens, such as pollens, and perennial rhinitis was associated 
with indoor allergens, such as dust mites, moulds, and animal dander. As this classification 
was regarded as insufficient, the revised classification adopted by Allergic Rhinitis and its 
Impact on Asthma (ARIA) divides rhinitis according to frequency and duration of symptoms 
into “intermittent” and “persistent”, and according to severity (based on symptoms and 
quality of life) into “mild” or “moderate/severe” 136.  
The prevalence of rhinitis is increasing worldwide 137, and the estimated prevalence in 





Community Respiratory Health Survey (ECRHS) 124. However, studies describing other features 
of Portuguese rhinitis patients are scarce in the literature.  
In order to increase the current knowledge about rhinitis patients in Portugal, we aimed at 
characterising the adult population with rhinitis attending the Allergy Clinic of the Cova da 
Beira Hospital between the years of 2003 and 2007, as well as assessing the relationship 
between rhinitis and asthma. 
 
3.2.3. Materials and Methods 
Patients referred by General Practitioners and ENT surgeons to the Allergy Outpatient 
Clinic of the Cova da Beira Hospital between 2003 and 2007 for suspected allergic rhinitis 
were sequentially studied. 
The diagnosis of rhinitis was based upon clinical history, physical examination with anterior 
rhinoscopy, and response to medication. Skin prick testing to aeroallergens and 
determination of total and specific IgE were also performed in rhinitis patients to 
determine the presence of atopy. Sensitisation profiles were analysed both by skin prick 
tests and specific IgE. Skin prick testing included a first panel containing the 35 most 
prevalent aeroallergens in the region. According to results from this initial battery, as well 
as from clinical history, a second panel with more specific aeroallergens was also tested. 
For presentation of results, among the other allergens, the grass family (Poaceae) was 
divided into “grass” (non-cultivated Poaceae) and “cereal” (cultivated Poaceae).  
Assessment of severity and frequency of disease was based on the revised classification of 
allergic rhinitis adopted by ARIA, even for non-allergic rhinitis 136. All patients were 
specifically examined in terms of concurrent asthma by filling in a questionnaire, clinical 
examination and lung function testing (for those patients with a positive questionnaire). In 
addition, patients were also examined to assess other existing co-morbidities. 
The designation of “non-allergic” was applied when the history, skin prick testing, and 
serum specific IgE measurements included in the allergy examination were all negative. 
County administrative centres with predominantly industrial or tertiary services were 
considered “urban”. Remaining centres were regarded as “rural”.  
The study protocol was approved by the Hospital Ethics Committee. 
All data were analysed using non-parametric tests. Results are expressed as medians and 
range. Wilcoxon signed rank test was used for comparisons within groups and Mann 





variables) for comparisons between groups. The association of various clinical parameters 
was analysed using the Spearman rank correlation test. A p value of less than 0.05 was 
considered significant. All analyses were performed using Minitab 14 for Windows. 
 
3.2.4. Results 
The total population analysed included 1092 patients, which represents 86% of all the 
patients in our clinic. From those, we excluded all patients under 18 years of age and 
patients without a permanent residence in the region. In addition, 32 patients were 
excluded because of discordance between clinical history, skin prick tests and specific IgE 
tests. Patients with hormonal, infectious or anatomic rhinitis were also excluded. 
Six hundred and eighty six patients, all adult Caucasian, (473 females), living in the Cova da 
Beira area were included for further study.  
Seventy two percent (494) of the patients had a diagnosis of AR and twenty eight percent 
(192), had NAR. Demographically, there were significant differences between the two 
groups. There were more women among NAR than among AR patients, with female: male 
ratios of 3.6 and 1.9, respectively (p=0.001). In addition, AR patients were significantly 
younger than NAR patients (median age 33 (18-102) vs. 47 (18-84) years, p=0.001). 
Smoking habits (recorded as pack-years) were not different between AR and NAR patients. 
Rhinitis was classified according to the old practice that divided it into seasonal and 
perennial. As expected, we observed that seasonal symptoms were more common in AR 
than in NAR patients (36.7% vs.15.5%, χ2= 22.354, p< 0.001).  
Patients were divided into three age groups; severity and duration of symptoms were 
classified according to the ARIA guidelines 136. Severity did not increase with aging, either 
in AR or in NAR patients (χ2=0.704 for allergic and 2.844 for non-allergic, p>0.05). 








Figure 7 – Profiles of disease severity in different age groups of non-allergic rhinitis (Panel A) and 
allergic rhinitis (Panel B) patients.  
Patients were grouped into three age groups and severity was assessed according to ARIA 
guidelines. Severity did not increase with age and was not statistically different between the two 
groups. 
 
Rhinitis is frequently associated with bronchial involvement (even in NAR) and with other 
diseases. We studied clinical associations present in our population and observed that the 
great majority of them also had asthma. Although overall there were more allergic than 
non-allergic asthmatic patients, a significantly higher percentage of NAR than AR patients 
had concurrent asthma (87% vs 75%, respectively; p < 0.001; Chi-square Test). Severity of 
rhinitis did not correlate with that of asthma. In addition, a significantly higher percentage 
of NAR than AR patients had sinusitis, pharyngitis, urticaria and drug allergy. In contrast, a 
lower percentage of NAR than AR patients had conjunctivitis (Figure 8).  
 
Figure 8 – Main co-morbidities associated with rhinitis.  
Allergic rhinitis patients (light bars) had a higher prevalence of conjunctivitis, whereas non-allergic 







We used anterior rhinoscopy to detect and characterise nasal polyposis. No significant 
differences in terms of the percentage of patients with nasal polyps were observed between 
AR and NAR patients (4.4% (22 patients) vs 2.8% (5 patients); p=0.399; Fisher’s Exact 
Test). Nasal polyposis was not associated with more severe rhinitis in either RA (p=0.11; 
Chi-square test) or NAR (p=1.0; Fischer’s Exact Test) patients. Curiously, in AR (p=0.05; 
Chi-square test), but not in NAR (p=0.61; Fischer’s Exact Test) patients, there was a trend 
for significant association of nasal polyposis with the presence of bronchial asthma. Finally, 
in AR patients, nasal polyposis was not significantly associated with preferential 
sensitisation to seasonal or perennial allergens. 
As expected, total serum IgE was significantly higher in allergic than in non-allergic 
patients (median 177 (3-5000 kU/L) vs. 26 (<2-865 kU/L), p<0.001). There was no 
correlation between total IgE levels and features of allergic sensitisations (wheal size on 
skin prick tests or specific IgE levels). 
In AR patients, the frequency of sensitisations evaluated by skin prick testing was 64.7% 
for grass pollen, 61.4% for mites, 59.2% for cereal pollen, 56.6% for weed pollen, 49.5% 
for tree pollen, 32.7% for cat dander, 29.4% for dog dander, and 23.5% for moulds and 
fungi. The frequency of sensitisation evaluated by specific IgE tests was slightly different, 
but directly correlated with that from skin prick tests: 60.3% for grass pollen, 55.33% for 
mites, 51.3% for cereal pollen, 55.0% for weed pollen, 45.6% for tree pollen, 13.3% for cat 
dander, 11.7% for dog dander, and 2.7% for moulds and fungi. The percentage of 
monosensitised AR patients, as assessed by skin prick testing, was 7.0%, with 4.0% of them 
monosensitised to mites, 0.9% to grass pollen, 0.5% to tree pollen, 1.2% to weed pollen, 
0.2% to cat dander and 0.2% to dog dander. There were no AR patients monosensitised to 
cereal pollen or moulds.  
The major allergen sensitisers, as evaluated by skin prick testing and specific IgE, were 
mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae), grasses (Phleum pratense, 
Dactylis glomerata, Lolium perenne,Festuca eliator, Poa pratensis and Cynodon dactylon), cereals (Secale 








Figure 9 – Major aeroallergens in allergic rhinitis.  
Allergen sensitisation was evaluated by skin prick test with a battery of the most common 
aeroallergens in the local flora, as well as mites, moulds and animal dander. 
 
In spite of similar prevalence of these major allergens, there were significant differences in 
terms of the class/level of sensitisation as measured by wheal size and specific IgE values 
(χ2=161.692, p<0.0001, Figure 10), with higher sensitisation levels, (classes 5 and 6) more 
prevalent with grass pollens.  
We then went on to compare several features between urban and rural AR patients. Our 
population included 226 urban and 268 rural AR patients. The samples were paired for age 
and gender. 
The sensitisation profile was not significantly different between urban- and rural-based 
rhinitis patients, and the level of sensitisation was similar for all the allergens (p>0.05).  
Furthermore, there were no differences regarding severity of rhinitis between rural and 
urban allergic rhinitis patients and the same was valid for NAR patients. 
However, AR prevalence as compared to NAR was higher in urban- than in rural-based 







Figure 10 – Degree of sensitisation to aeroallergens in allergic rhinitis patients.  




Rhinitis is a major public-health problem that is increasing in prevalence in most developed 
countries 138. Many people with rhinitis self-manage the condition with over-the-counter 
products, do not seek a physician’s help, confuse it with recurrent infectious disease, or 
indeed do not recognise rhinitis as a condition needing treatment. This leads to 
subdiagnosis and impaired quality of life. 
In the present study, we present data from a Portuguese patient population with rhinitis. As 
far as we know, this is the first full characterisation of Portuguese patients with rhinitis, 
involving not only epidemiological but also clinical aspects. We studied several aspects 
involving rhinitis in an allergy outpatient clinic. Our diagnosis of rhinitis was based upon 
subjective clinical symptoms as reported by the patients, but also on more objective aspects 
such as anterior rhinoscopy, allowing characterisation of turbinate swelling and rhinorrhea. 
Furthermore, the latter technique was also crucial for confirming the presence of nasal 
polyposis in our patients. 
In this study, twenty eight percent of our rhinitis patients were non-allergic. These NAR 
patients were older, predominantly female, and, very interestingly, had a higher prevalence 
of asthma than AR patients. In line with these findings, the ECRHS reported a frequency 





with asthma among NAR patients 139. Overall, our patients had a high prevalence of 
bronchial asthma. This is in contrast with the known prevalence of asthma in patients with 
allergic rhinitis in the general population, which may average between 25% and 40% 136, 138 
However, since we are a specialised clinic and not a general practitioner office, most 
patients referred to our outpatient clinic tend to have more severe and long-standing 
rhinitis, which increases the likelihood of having developed concurrent bronchial asthma.  
In recent years, the key concept of “one airway, one disease” has emerged 136. The majority 
of allergic asthma patients concomitantly have rhinitis, and some of the AR patients have 
asthma 136, 138. In the ECRHS, an association between asthma and rhinitis was observed 
(even in non-atopic individuals), and asthma attacks were reported more often where there 
were high prevalences of nasal allergies 124, 128. This association between rhinitis and asthma 
was not fully explained by shared risk factors, (including total IgE levels, parental history of 
asthma, or sensitisation to allergens), or genetic predisposition to atopic diseases 139. 
Moreover, rhinitis is a significant risk factor for the occurrence of asthma, independently of 
allergy 140. In a study by Leynaert et al., asthma was strongly associated with rhinitis not only 
among atopic subjects (odds ratio (OR) =3.1; 95% confidence interval 2.4-4.0), but also 
among non-atopic subjects (OR=6.2; 95% confidence interval 4.3-8.8) 128. In addition, 
having co-morbid allergic rhinitis is a marker for the presence of more-difficult-to-control 
asthma and worsened asthma outcomes 141, 142. Concomitantly, there is considerable 
reduction in asthma morbidity in individuals with asthma and rhinitis, when the latter is 
properly treated 138. 
Curiously, in our study, more NAR than AR patients had drug allergies, most of these were 
related to aspirin intolerance. Some NAR patients had concomitant asthma, aspirin 
intolerance and urticaria. Aspirin and other anti-inflammatory drugs can precipitate adverse 
reactions in bronchial asthma and urticaria. There is also a distinct clinical syndrome, 
“aspirin-induced asthma” or the aspirin triad, characterised by nasal polyposis, aspirin 
sensitivity and asthma 143.  
Similarly, in our study, chronic pharyngitis and sinusitis were more frequent in NAR. This 
is most likely due to the fact that rhinitis tends to be more difficult to control in these 
patients and is often associated with more persistent post-nasal dripping that may 
contribute towards inflammation in the pharynx. 
In a survey in a representative sample of the Belgian population, that evaluated both AR 
and NAR, the authors found a high prevalence of self-declared rhinitis, with AR being 





greater number of co-morbidities (asthma, skin allergy and food allergy), and displayed a 
more severe profile than NAR patients 144. However, no clinical evaluation was carried out 
to confirm the diagnosis, and no data on IgE-mediated allergy were known. 
A similar study in Danish adolescents and adults showed that subjects with AR more often 
suffered from asthma, food allergy and conjunctivitis, whereas patients with NAR suffered 
more frequently from recurring headaches and sinusitis 145. This study included clinical 
evaluation, spirometry and skin prick testing; however, as it is very clearly pointed out by 
the authors, only the 10 most common allergens were tested and no total or specific IgE 
was measured, leading to overlooked subjects with AR being included as NAR patients. 
 
Nasal polyposis is a factor that can significantly decrease the quality of life of patients with 
rhinitis and even worsen underlying bronchial asthma. It was curious to notice that, 
although a relatively high percentage of our patients had moderate/severe persistent 
rhinitis, the prevalence of nasal polyposis was low, both in AR and NAR patients. We 
believe that the prevalence we found is representative of the true values within this 
population since all patients were also specifically asked about nasal obstruction (visual 
analogue score) and were analysed using anterior rhinoscopy. However, since not all 
patients were co-jointly observed with the ENT Department, not all patients underwent 
nasal endoscopy or CT scan of the nose and nasal sinuses. We therefore have to accept that 
some patients with clinically silent nasal polyposis may have escaped our diagnosis.  
Overall, no significant differences in terms of the percentage of patients with nasal polyps 
were observed between AR and NAR patients in our study. This is not surprising since 
various reports in the literature, focusing on the relationship between allergy, rhinitis and 
nasal polyposis have shown discrepant results. In fact, although some authors have shown 
a higher prevalence of allergy in patients with nasal polyposis, varying between 54 and 64% 
146, 147, others have not shown any association at all 148, 149, 150. Differences in the 
methodological approach as well as different genetic populations may account for these 
differences. 
In our study, nasal polyposis was not associated with more severe rhinitis in either RA or 
NAR patients. This was surprising since we expected the more relevant underlying 
inflammation in patients with more severe underlying rhinitis to be associated with a 
facilitated development of nasal polyps.  
Importantly, there was a trend for AR (but not NAR) patients with nasal polyposis to have 





in terms of general asthma. For instance, in a population-based study, Johansson and 
co-workers, described that nasal polyps were more frequent in patients with bronchial 
asthma 151. However, some authors have reported that non-allergic asthma is more 
frequently associated with nasal polyposis 152. The discrepancy between these results and 
our own may be due to the low numbers of patients with nasal polyps who were not 
allergic in our patient population. Another possibility is that the differences may be due to 
the number of years with the disease, which was not similar in the two studies. Finally, and 
since our study tended to have a high proportion of patients with moderate/severe rhinitis, 
genetic differences may account for the observed differences. In fact, some genetic 
polymorphisms in IL-1 and IL-4 genes have been described in some populations, which 
increase or decrease the likelihood of developing nasal polyps 153, 154. Such polymorphisms 
should also be studied in our population. 
Grass pollen is the major cause of pollinosis in the Mediterranean region of Europe 155. In 
our AR patients, major allergic sensitisers included the Poaceae family (grass and cereal 
pollens) and mites, with a low percentage of monosensitisation. There was a high degree of 
cross reactivity among the grass pollens. Olive tree and Parietaria were other major causes 
of sensitisation in this population. However, monosensitisation to olive tree pollen was not 
frequent. Interestingly enough, patients sensitised to Parietaria had perennial symptoms, 
possibly due to the long persistence of the pollen in the atmosphere, given current climatic 
changes 155. We used a battery of 35 screening aeroallergen extracts some of which were 
mixtures of allergens. When these were positive, we further performed skin prick testing 
with the individual allergens. Although, theoretically, this approach may be associated with 
a higher rate of false positive results, we do not believe this is the case since we used highly 
tested commercial extracts each of which was selected by our team as the ones having the 
highest positive predictive value. Furthermore, clinicians performing the tests were highly 
trained in the technique. 
This sensitisation profile is in agreement with a previous study that analysed aeroallergen 
sensitisation in the population of Cova da Beira, and which observed a similar pattern of 
sensitisation with a mixture of grasses, Olea europea, and Parietaria judaica as the most 
representative sensitisers 129.  
The Iberian study of aeroallergen sensitisation in AR reported similar results with common 
polysensitisation, involving both mites and pollens, without significant differences between 





In the present study, we provide, for the first time, data on the magnitude of sensitisations 
for the major allergens in Portuguese AR patients. We show that there are significant 
differences in terms of the level of sensitisation, as measured by specific IgE classes. In 
spite of similar prevalence within the major allergens, a particular species or family seems to 
be preferentially associated with high levels of specific IgE, as happens with timothy 
(Lolium perenne), in contrast to olive tree (Olea europea). This may suggest that those allergens 
are the principal determinants of clinical symptoms. In fact, a correlation between serum 
allergen-specific IgE and severity of perennial allergic rhinitis was found in children 156. 
Accurate identification of the specific cause of allergic rhinitis is important for the 
implementation of avoidance measures and immunotherapy. 
 
Epidemiological studies carried out in different geographical regions in the world have 
shown a significant and consistent association between levels of airborne pollutants (diesel 
exhaust particles, ozone, nitrogen dioxide, and sulphur dioxide) and increased asthma and 
rhinitis symptoms 132. Similar data was obtained from experimental studies carried out in 
humans and animals 157. In addition, rural living, especially on a farm, has been inversely 
associated with asthma, hay fever and atopy in children 158, 159. Thus, the “rural protection 
phenomenon” may be a combination of both mechanisms.  
Surprisingly enough, in terms of allergen sensitisation in urban- and rural-based AR 
patients, we found no differences in prevalence. This is in disagreement with a similar study 
which demonstrated that the prevalence of sensitisation to grasses, weeds and Olea europea 
was higher in the urban group 131. Furthermore, prevalence of AR was found to be higher 
in urban than in the rural patients. This is because in urban areas, pollen grains can interact 
with fuel residues and combustion products, and this may modulate the allergenic epitopes 
and increase their allergenicity 132.  
In a previous study in asthmatic patients of this region we did observe differences in the 
sensitisation profile with a higher prevalence of tree pollen allergy in the rural context and a 
higher prevalence of sensitisation to moulds in the city 160. This fact could be related to the 
allergenic particles’ size, and to how deep they can travel along the airways. In fact, intact 
pollen grains typically do not enter the lower regions of the respiratory tract, and main 
symptoms are located in the eyes, nose and nasopharynx 155.  
 
One limitation of our study is that the sample of adults with rhinitis was drawn from a 





patients with rhinitis, since patients treated by specialists appear to have more severe 
symptoms than those seen by general practitioners. In addition, severity of rhinitis in these 
patients was classified at the first appointment, even though many of them were not 
treatment-naïve at that time. Previous studies in Portugal obtained discrepant results from 
those presented here, but different methodological approaches were used, as the majority 
of them were only questionnaire-based, whereas our study also included clinical parameters 
(anterior rhinoscopy) 129, 130. 
 
In summary, in this study, bronchial asthma was more frequently associated with NAR 
than with AR. However, the two kinds of rhinitis could not be differentiated in terms of 
severity of clinical symptoms. Nasal polyposis was more frequently associated with 
bronchial asthma, in allergic patients. 
The major allergens in the area were grass pollen, cereal pollen, mites and olive tree. 
Monosensitisation was uncommon and it mainly included mites. Interestingly enough, the 
magnitude of sensitisation was different among the major allergens, with Graminea pollen 
as both one of the major allergens and the one with the highest levels of sensitisation. 
Urban and rural-based AR patients had no different sensitisation profiles, and could not be 
differentiated in terms of severity of their disease. 
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3.3. Functional Characterisation of CD8+CD28+ and 
CD28− T Cells in Atopic Individuals sensitised to 
Dermatophagoides pteronyssinus  




For more than thirty years several investigators have suggested that CD8+ T suppressor 
cells played an important role in immunoregulation. Recent studies, mainly in 
transplantation and autoimmunity models, characterised this suppressor population by the 
lack of the co-stimulatory molecule CD28. These CD8+CD28− T cells are phenotypically 
and functionally different from CD8+CD28+ T cells and are expanded in rejection-free 
transplanted patients. Less is known about the former cells in atopy. 
The aim of the present study was to analyse the phenotype and functional properties of 
human CD8+CD28− T cells upon allergen-specific PBMC proliferation in atopic and 
non-atopic individuals. 
Methods 
Peripheral blood mononuclear cells were obtained from atopic and non-atopic volunteers, 
after density gradient centrifugation.  CD8+CD28− and CD8+CD28+ T cells were 
isolated using immunomagnetic beads, and the relative percentages and phenotypic 
markers  were analysed by flow cytometry. Phenotypic studies included NK cell markers, 
chemokine receptors, activation markers as well as α/β and γ/δ TCR chains. Proliferation 
studies were performed in the isolated populations and also in co-cultures with PBMC 
using Dermatophagoides pteronyssinus as a stimulus. Proliferation was assessed by thymidine 







The relative percentages of CD8+CD28− T cells and their phenotypic expression in atopic 
and non-atopic volunteers were not significantly different. However, CD8+CD28− T cells 
proliferated more than CD8+CD28+ T cells when stimulated with Der p, although the 
cytokine synthesis was similar. In terms of allergen-induced proliferation in the co-cultures, 
CD8+CD28− co-cultures with PBMC proliferated more than CD8+CD28+ T cells 
co-cultures, but the cytokine synthesis patterns were alike. 
Conclusions 
Our data confirms phenotypic and functional differences between CD28+ and CD28− T 
cells, irrespectively of the atopic status. Purified CD8+CD28− T cells freshly isolated from 
the peripheral blood do not have suppressor properties neither over PBMC 
allergen-specific proliferation nor on cytokine synthesis. 
 
3.3.2. Introduction 
T cells that use non-cytolytic mechanisms to down-regulate the immune response 
(suppressor T cells or Ts) are thought to play an essential role in controlling reactivity to 
foreign antigens and inducing tolerance to self antigens 161. Nevertheless, more than three 
decades since their discovery, an understanding of the mechanisms whereby suppressor 
cells exert their activity is still incomplete.  
Phenotypically, CD8+ Ts are characterised by the lack of the CD28 co-stimulatory 
molecule 162. CD8+CD28− T cells are thought to arise from CD8+CD28+ T cells that 
have proliferated several times since they have shorter telomeres 41 and share oligoclonal 
expansions 163. In vitro, CD8+CD28− T cells arise from CD8+CD28+ T cells repeatedly 
stimulated in the presence of interleukin (IL)-2 59. In contrast, IL-4 can block this 
differentiation 43. 
Recent evidence has been accumulating to show that CD8+CD28− T cells can inhibit T 
helper cell activation and proliferation in mitogen and antigen-driven responses 50, 70, 86. In 
vitro, antigen-specific CD8+CD28− T suppressor cells have been generated by multiple 
rounds of stimulation of human CD8+CD28+ T cells with APC either from an allogeneic 
or a xenogeneic donor 70, 164. The generated cells expressed FOXP3 56, a gene related with 
regulatory function, and could inhibit proliferation of CD4+ T cells interacting directly 





Non-antigen specific CD8+CD28− T cells with suppressor activity have also been 
generated from CD8+CD28− T cells in the presence of IL-2 and IL-10 72. These 
suppressor cells inhibited both antigen-specific CD4+ T cell proliferation and cellular 
cytotoxicity by secreting cytokines such as IFN-γ, IL-6 and IL-10 82, 83. Defects in this 
antigen-nonspecific suppression have been described in multiple sclerosis 83 and in patients 
with systemic lupus erythematosus 81, and are primarily seen in chronic progressive 
situations.  
Atopic allergic diseases are immune disorders caused by aberrant Th2 cell-dominated 
responses to otherwise innocuous substances, such as proteins from house dust mite or 
grass or tree pollen 133. Many authors believe that atopy and allergic diseases are the result 
of inadequate or impaired inhibition of allergen-specific T helper-type responses by the 
regulatory T cells 115, or even a consequence of decreased frequencies of those cells in 
atopic individuals 116. There is a growing body of evidence which suggests that CD8+ T 
cells play an important part in regulating the IgE response to non-replicating antigens 91, 93. 
Nonetheless, the presence of CD8+ suppressor T cells in human atopic patients is not yet 
confirmed.  
The aim of the present study was to analyse the functional properties of human 
CD8+CD28− T cells upon Dermatophagoides pteronyssinus (Der p)-specific PBMC 
proliferation in atopic and non-atopic individuals. 
 
3.3.3. Materials and methods 
Subjects 
Peripheral blood was obtained from 30 non-atopic and 32 atopic (with allergic rhinitis) 
adult volunteers (Caucasian, non-smokers), paired for age and gender. Atopic volunteers 
were recruited from the allergy clinic of the Cova da Beira Hospital and the non-atopic 
volunteers were recruited among the Hospital and the University staff. 
Atopy was assessed by positive skin prick tests and specific IgE levels to Der p. Volunteers 
who received immunotherapy or were on systemic medication were excluded. Pregnant or 
breastfeeding women and all volunteers with disease affecting the immune system were 
also excluded.  
The study was approved by the Hospital Ethics Committee. Informed written consent was 






The following monoclonal antibodies (mAbs) were used: anti-CD3 mAb conjugated with 
APC was purchased from Pharmingen (San Diego, CA, USA), anti-CD8 mAb conjugated 
with PerCP was purchased from Becton Dickinson (San José, CA, USA), and anti-CD28 
mAb conjugated with FITC was purchased from Pharmingen. 
Blood preparation and antibody staining 
Freshly collected peripheral blood mononuclear cells (PBMC) were stained from whole 
blood after lysis of the erythrocytes (10mM Tris, 0.15M NH4Cl, pH=7.4). Staining was 
performed at 4°C for 30 min in staining solution (PBS, 0.2% bovine serum albumin (BSA), 
0.1% NaN3) in round-bottomed microtiter plates (Greiner, Nürtingen, Germany) with ≈ 
0.5x106 cells/well. After staining, the cells were washed, resuspended in 500μl PBS and 
acquired in a FACSCalibur Flow cytometer (Becton Dickinson). 
Flow cytometry analysis 
Data were collected on 20.000 cells/sample using FACSCalibur flow cytometer equipped 
with an argon ion laser and a red diode laser, for quantification of CD28+ and CD28− T 
cells. Anti-CD8, −CD3, and −CD28 monoclonal mAb were used to define the 
CD3+CD8+CD28+ and CD28− T cell populations. T lymphocytes were gated for analysis 
based on light scattering properties and on CD3 staining. Positively and negatively stained 
populations were calculated by quadrant dot plot analysis determined by isotype controls. 
For phenotypic analysis of the defined subpopulations, 30.000 events were collected per 
sample. Fluorescence dot plots and histograms were analysed using cytological software 
(Cell Quest Pro, Becton Dickinson). Phenotypic analysis of the TCRαβ and TCRγδ was 
also performed on the isolated fractions of CD3+CD8+CD28+ and CD28− T cells. 
Cell isolation 
Peripheral blood mononuclear cells (PBMC) from the volunteers were separated from 
peripheral blood (120ml) by centrifugation over Lymphoprep. Lymphocytes were further 
purified by allowing the cells to adhere to plastic for 1h at 37°C, 5%CO2.  CD8+ T cells 
were isolated from the supernatant by negative selection using magnetic beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). To separate CD28+ and CD28− T cells from 
CD8+ cell suspensions, cells were incubated with CD28-FITC mAb (Pharmingen) and 





85% as evaluated by flow cytometry analysis. The adherent fraction was collected as well 
and used as APC in cell cultures after mitomycin treatment. 
Cell Cultures 
Responder cells were cultured at a concentration of 0.5x106 cells/ml for 6 days in RMPI 
1640 complete medium [RPMI 1640, 2mM L-glutamine, 1% antibiotic/antimicotic (Sigma-
Aldrich, St Louis, MO, USA), and 10% foetal calf serum (Biochrom, Berlin, Germany)] in  
96-well flatt-bottomed plates (Nunc, Roskilde, Denmark) with or without APC and 
10µg/ml purified Der p extract (a kind gift from Dr. Joost Van Neerven, The Netherlands). 
For positive control, cells were incubated with 0.5µg/ml OKT3 (eBiosciences,San Diego 
USA) or with 5µg PHA (Sigma-Aldrich) for 3 days in the same conditions as for Der p. 
Fourteen hours before the end of the culture [3H]-thymidine was added to the wells 
(1µCi/well). [3H]-thymidine (Amersham Biosciences, Uppsala, Sweden) incorporation was 
determined by scintillation counts in a TopCount (PerkinElmer, MA, USA) and results 
were expressed as counts per minute (cpm). Mean cpm of the triplicate cultures and 
standard error of the mean were calculated. 
Culture conditions were as follows: CD8+CD28+ cells alone, CD8+CD28− cells alone, 
CD8+CD28+ cells + APC + Der p, and CD8+CD28− cells + APC + Der p. 
Cell co-cultures 
PBMC (0.5x106 cells/ml) were incubated in different proportions (1:1, 2:1, 4:1) with freshly 
isolated CD8+CD28+ and CD8+CD28− T cells for 6 days in 96-well flatt-bottomed 
plates with and without 10μg/ml Der p extract. Tritiated thymidine (1μCi/well) was added 
14 hours prior the end of the culture. Cells were harvested on fibber filters, and 
incorporated thymidine was determined by scintillation counting.  
Cytokine production 
For soluble cytokine detection in the culture supernatants, the human Th1/Th2 cytokine 
bead array kit was used, according to the manufacturer’s instructions (Becton Dickinson). 
Statistical analysis 
Statistical analysis of the results was performed using Minitab 14 statistical Software. Mann 
Whitney U test was used to assess differences between atopic and non-atopic volunteers. 
Wilcoxon signed rank test was used to assess differences within the same population. A p 







In order to assess the proliferative response to allergen of CD8+CD28+ and CD28− T 
cells, we set up cultures of isolated fractions with and without APC and Der p. As shown in 
Figure 11, contrary to what occurred with unstimulated cells, CD8+CD28− T cells 
proliferated when stimulated with Der p, displaying a significantly higher level of 
proliferation as compared with CD8+CD28+ T cells in atopic and non-atopic individuals 
(p= 0.001). However, the proliferation was not significantly different between atopic and 
non-atopic volunteers (p>0.05).  
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Figure 11 – CD8+CD28− T cells proliferate more than CD8+CD28+ T cells when stimulated with 
Der p. 
Isolated CD8+CD28− and CD8+CD28+ T cells from 8 atopic and 10 non-atopic volunteers were 
incubated for 6 days in 96-well flat-bottomed plates with and without 10µg/ml Der p extract. 
Tritiated thymidine (1µCi/well) was added 14h prior to the end of the culture. Cells were harvested 
on fibber filters, and incorporated thymidine was determined by scintillation counting. Results show 
thymidine incorporation (cpm, mean ± sem). Wilcoxon signed ranked test was used for comparison 
between conditions 
 
We also stimulated isolated fractions with OKT3 and, in this case, CD8+CD28− T cells 
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Figure 12 – CD8+CD28− T cells proliferate more than CD8+CD28+ T cells when stimulated with 
Der p but less with a polyclonal stimulus.  
Isolated CD8+CD28+ and CD8+CD28− T cells from non-atopic volunteers were incubated for 6 
days in 96-well flat-bottomed plates with and without 10μg/ml Der p extract and for 3 days with 
0.5μg/ml OKT3. Tritiated thymidine (1μCi/well) was added 14 hours prior the end of the culture. 
Cells were harvested on fibber filters, and incorporated thymidine was determined by scintillation 
counting. Results show thymidine incorporation (cpm, mean ± sem) for 10 volunteers (5 females, 
aged 22-25 years). Wilcoxon signed rank test was used for comparison between conditions. 
 
Cytokine synthesis was studied using the cytometric bead array (CBA) in culture 
supernatants collected on day 3. None of the cultures synthesised IL-5, IL-4 or IL-2, but all 
the Der p-stimulated cultures synthesised IFN-γ, TNF-α and IL-10. However, we did not 
observe statistically significant differences either between the cultures with CD8+CD28+ 
and CD28− T cells or between atopic and non-atopic individuals (Figure 13). 
 
 
Figure 13 – Cytokine synthesis is similar for both isolated populations. 
Isolated CD8+CD28− and CD8+CD28+ T cells from 4 atopic (Panel A) and 3 non-atopic (Panel B) 
volunteers were incubated in 96-well flat-bottomed plates with and without 10µg/ml Der p extract. 
On day 3, culture supernatants were collected and cytokine synthesis (IFN-γ, TNF-α, IL-10, IL-5, 
IL-4, and IL-2) was evaluated by cytometric bead array, following the manufacturer’s protocol. 
Values shown are mean ± sem. Mann-Whiney U test was used for comparison between atopic and 






In order to study the potential suppressor properties of the isolated subpopulations, we 
performed co-cultures with PBMC at different ratios. None of the isolated subpopulations 
was able to suppress the allergen-specific PBMC proliferation, since we observed an 
increase in cpm counts (Figure 14). 
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Figure 14 – CD8+CD28− co-cultures with PBMC proliferate more than CD8+CD28+ co-cultures. 
Isolated CD8+CD28− and CD8+CD28+ T cells from 8 atopic and 6 non-atopic volunteers were 
incubated in different proportions with PBMC for 6 days in 96-well flat-bottomed plates with and 
without 10µg/ml Der p extract. Tritiated thymidine (1µCi/well) was added 14h prior to the end of the 
culture. Cells were harvested on fiber filters, and incorporated thymidine was determined by 
scintillation counting. Results show thymidine incorporation (cpm, mean ± sem). Wilcoxon signed 
ranked test was used for comparison between conditions. 
 
Cytokine synthesis was also evaluated by CBA, in the co-culture supernatants on day 3 and 
on day 5. Synthesis of IL-5, IL-4 and IL-2 was very low in all the cultures. When cytokine 
synthesis was compared between day 3 and day 5, only IFN-γ synthesis increased in the 
co-cultures. There were no significant differences in cytokine synthesis either between 
cultures from atopic and non-atopic individuals or between co-cultures with CD8+CD28− 










Figure 15 – Cytokine synthesis is similar in all the co-cultures stimulated with Der p extract. 
Isolated CD8+CD28− and CD8+CD28+ T cells from 4 atopic and 3 non-atopic volunteers were 
incubated in a proportion of 1:1 with PBMC in 96-well flat-bottomed plates with and without 
10µg/ml Der p extract. On day 3 and day 5, culture supernatants were collected and cytokine 
synthesis (IFN-γ, TNF-α, IL-10, IL-5, IL-4, and IL-2) was evaluated by cytometric bead array, 
following the manufacturer’s protocol. Values shown are mean ± sem. Mann-Whiney U test was 
used for comparison between atopic and non-atopic volunteers and Wilcoxon signed rank test was 
used for comparison between conditions. 
 
3.3.5. Discussion 
This is the first study on suppressor function of CD8+CD28− T cells in allergy. Previous 
studies on the regulation of atopic allergy mainly included natural T regulatory cells 
(CD4+CD25+) and showed inconclusive results 165, 166. We believe that this study can 
enhance the knowledge and shed some light on the functional properties of the 
CD8+CD28− T cells and their implication in the development of atopy. 
In previous studies, we observed that CD8+CD28− T cells are not phenotypically different 
between atopic and non-atopic individuals. This may imply that atopy is not associated 
with a specific phenotype of CD8+ T cells. However, it is important to mention that our 
data on phenotypic differences between CD28+ and CD28− subpopulations is in line with 





related receptors in CD8+CD28− T cells, in a context where co-stimulation is not present, 
may be important towards limiting T cell cytolytic responses, and act as a form of 
“regulation”. 
Classical antigen-presentation studies showed that MHC class I molecules present peptides 
derived from proteins synthesized within the cell, whereas MHC class II molecules present 
exogenous proteins captured from the environment. Emerging evidence indicates, 
however, that dendritic cells have a specialised capacity to process exogenous antigens into 
the MHC class I pathway 167. Indeed we observed antigen-specific proliferation and 
cytokine synthesis by purified CD8+CD28− T cells when cultured with Der p which 
suggests that exogenous proteins can in fact be presented through the MHC class I 
pathway. 
In accordance with our expectations, unstimulated cells did not proliferate. Interestingly 
enough, CD8+CD28− but not CD8+CD28+ T cells proliferated in response to Der p, in 
the presence of APC. This fact suggests that CD28− T cell proliferation is not impaired in 
spite of the absence of CD28 co-stimulation 168 and that CD8+CD28− T cells respond to 
common aeroallergens. These results should be considered with caution as the two subsets 
of CD8+ T cells studied here are oligoclonal 163 with respect to their TCR, and the use of 
this allergen might stimulate an insignificant minority of clones and lead to inconclusive 
results. For this reason, we performed cell cultures for 3 days with OKT3 to confirm 
whether multi-clonal cellular responses were different in both subpopulations. Results 
showed a proliferation impairment in CD8+CD28− T cells which corroborates previous 
results  33, 47. This implies that our results must be confirmed by performing the same 
studies with another allergen. 
When cytokine production was analysed, no detectable IL-5, IL-4 and IL-2 production was 
induced by the allergen in CD28+ or CD28− T cells. On the other hand, IFN-γ, TNF-α 
and IL-10 were synthesised at similar levels by both isolated populations. Other 
investigators mention that a subpopulation of suppressor CD8+CD28− T cells synthesises 
IL-10, thus mediating the suppressive effect 72. Moreover, Seneviratne et al. linked low 
levels of IL-10 with severe atopic disease 16. Since both of our subsets produced IL-10, we 
performed the co-culture studies in order to evaluate the “regulatory” capacity of these 
cells. The production of cytokines varied between donors, but followed similar patterns. 
The failure to detect the other cytokines (IL-5, IL-4, and IL-2) in the supernatants does not 
necessarily imply that they are not synthesised but may also suggest that they are 





Finally, we performed co-culture studies and observed that freshly isolated CD8+CD28+ 
or CD8+CD28− T cells did not show suppressive properties, and were not able to inhibit 
allergen-driven PBMC proliferation or cytokine synthesis. These results are in line with 
previous reports namely by Suciu-Foca and Filaci groups 169, where suppressor 
CD8+CD28− T cells were only generated after multiple rounds of stimulation of PBMCs 
with allogeneic 69, xenogeneic 70 or antigen-pulsed 71 autologous APC. 
However, the presence of CD8+CD28− suppressor T cells in vivo was observed in 
transplanted patients without rejection 87. These facts may imply a need for an elevated and 
sustained contact with the antigen (hence the need for multiple rounds of stimulation) in 
order to generate antigen-specific suppressor cells. It would be interesting to further study 
suppressive properties of CD8+CD28− T cells, by using allergen-specific T cell lines 
developed from atopic and non-atopic volunteers. 
In summary, in the present study we have shown that atopy is not related to an altered 
relative percentage or specific phenotypes in CD8+CD28+ or CD28− human T cells. 
Freshly immunomagnetically isolated CD8+CD28+ or CD28− human T cells have distinct 
phenotypes and, although sharing similar cytokine production patterns, they proliferate at 
different levels to common stimuli. Both subpopulations show similar proliferation 
capacity in atopic and non-atopic individuals and do not have any suppressor capacity. 
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3.4. T Cells in Sputum of Asthmatic Patients are 
Activated Independently of Disease Severity or Control 




T cells play an important role in bronchial asthma. Although airway CD4+ T cells have 
been extensively studied previously, there are hardly any studies relating CD8+ T cell 
activation and disease symptoms. 
The aims of this study were to analyse the association between T cell activation in induced 
sputum T cells and asthma severity and control; and to evaluate T cell subpopulations in 
the same subgroups. 
Methods  
Fifty allergic asthmatic patients were recruited and lung function testing was performed. 
Airway cells were obtained by sputum induction via inhalation of hypertonic saline 
solution. CD3, CD4, CD8, CD28, CD25 and CD69 were studied by flow cytometry in 
whole induced sputum and peripheral blood T cells.  
Results  
Total induced sputum T cells and CD8+ T cells had a higher relative percentage of  the 
activation markers CD25 and CD69 in comparison with peripheral blood. In sputum, the 
relative percentage of CD25 was higher in CD4+ T cells when compared to CD8+ T cells 
and the reverse was true regarding CD69. However, neither disease severity nor control 






Both CD4+ and CD8+ T cells are activated in the lungs and peripheral blood of asthmatic 
patients. However, there is no correlation between T cell activation phenotype in the target 
organ and disease severity or control. 
 
3.4.2. Introduction 
Asthma is characterised by variable airflow obstruction, airway hyperresponsiveness, and 
chronic airway inflammation, involving activated eosinophils, mast cells, and T 
lymphocytes 170. Assessment of airway inflammation is important in asthma since it directly 
reflects the disease, whereas lung function testing and airway responsiveness are indirect 
measurements of the condition. Typically, airway inflammation has been assessed by 
bronchial biopsies or bronchoalveolar lavage (BAL) fluid. Examination of spontaneous or 
induced sputum has advantages over these invasive methods, as it is inexpensive, easy to 
perform, well-tolerated, non-invasive, safe and can be performed repetitively 171. The 
cellular composition of sputum correlates well with that of BAL, but to a lesser extent with 
that of bronchial biopsies 172, 173. In addition to cellular sputum composition, there is 
increasing interest in the analysis of cellular subtypes and activation, which can be 
performed using flow cytometry 174.  
Traditionally, type 2 CD4+ T cells (Th2), have been considered to be the most important T 
cell subset in the pathophysiology of asthma. In fact, cytokines synthesised by CD4+ T 
cells are able to activate eosinophils and promote B cell synthesis of IgE. CD8+ T cells 
have been regarded as much less important or even as negative regulators of allergic 
inflammation. It was suggested that CD8+ T cells can contribute to the pathology of 
asthma death due to an enhancement of pre-existing airway inflammation in response to 
viral infection 112, 113. Furthermore, human airway CD8+ T cells spontaneously produce 
increased type 1 and type 2 cytokines in subjects with asthma when compared to healthy 
controls 11.  
Airway inflammation in asthma, involving activated eosinophils, mast cells and T 
lymphocytes can have varying degrees, and clinically, correlates with disease severity 175. In 
fact, asthma guidelines recommend stepwise increments in anti-inflammatory medication to 
control increased disease activity 120. However, few studies have analysed the relationship 





The aims of this study were to compare T cell subpopulations and activation status 
between peripheral blood and induced sputum in asthma, and to correlate relative 




3.4.3. Materials and Methods 
Volunteers 
Fifty adult allergic asthmatic patients were recruited from the Allergy Clinic of the Cova da 
Beira Hospital and lung function testing was performed. Asthma was defined according to 
the American Thoracic Society criteria 176. Allergy was confirmed by clinical history, skin 
prick testing, and determination of total and specific IgE. Asthma severity was assessed at 
the first appointment, according to the Global Initiative for Asthma (GINA) guidelines 120, 177. 
Asthma control was assessed by the Asthma Control Test (ACT) 178, just before the induction 
of sputum. None of the patients had changes in the medication or respiratory infections in 
the month prior to the induction, and none was on oral steroids. 
The study was approved by the Hospital Ethics Committee and all subjects gave their 
written informed consent. 
Sputum induction 
All patients were given detailed information and clear instructions prior to the procedure. 
Before sputum induction, all patients inhaled 12μg formoterol via a metered dose inhaler. 
Sputum was induced and processed according to the method described by Pizzichini et al. 
172 with minor modifications. 
Baseline peak expiratory flow (PEF) was measured prior to induction, and the 
measurement was repeated following formoterol, and after each 5 minute inhalation of 
nebulised hypertonic saline (5%). The procedure was stopped if PEF fell by >20% at any 
time, or if bothersome symptoms occurred. After each period of inhalation, volunteers 
were asked to rinse their mouth with water and blow their nose, and attempt to cough 







Unselected sputum was weighed and 0.1% dithiothreitol (DTT, Sigma-Aldrich, Saint Louis, 
MO, USA) in phosphate buffered saline (PBS) was added at a ratio of 4 ml to 1g sputum. 
The sputum was incubated with DTT at room temperature for 15 minutes on a rolling 
mixer. The same volume of PBS (4ml to 1g sputum) was added to the mixture and 
incubated for another 10 minutes. The suspension was then filtered through a 40μm cell 
strainer (Falcon). The filtrate was centrifuged at 500g for 10 minutes at room temperature 
to pellet cells. After two washing steps, cells were resuspendend in PBS and viability was 
determined by tryptan blue (Sigma-Aldrich) exclusion staining in a Neubauer 
haemocytometer (Merck Eurolabs, Lutterworth, UK). 
PBMC preparation 
Peripheral blood mononuclear cells (PBMC) were separated from 20ml heparinised 
peripheral blood using Lymphoprep (Nycomed, Oslo, Norway), washed twice in RPMI 
1640 (Sigma Aldrich) without additives and counted. 
Flow cytometry 
Sputum cells and PBMC were washed in PBS containing 0.1% sodium azide (Sigma-
Aldrich) and 0.4% bovine serum albumin (Sigma-Aldrich) (staining medium) and 
centrifuged at 300g. For each test, approximately 500.000 lymphocytes were incubated with 
fluorochrome stained antibodies for 30 minutes at 4ºC in the dark. Cells were then washed, 
resuspended in PBS and acquired using a FACSCalibur flow cytometer (Becton Dickinson, 
San Jose, CA, USA). Up to 20 000 CD3 positive events were collected per sample. All 
samples were stained with an APC-conjugated anti-human CD3 monoclonal antibody 
(mAb), FITC conjugated anti-human CD4 mAb, and PerCP conjugated anti-human CD8 
mAb. To assess surface marker expression, samples were incubated with anti-CD25, 
-CD69, or -CD28 PE-conjugated mAbs (Becton Dickinson). Isotype-matched antibodies 
were used as controls. The number of positive cells for each surface marker was expressed 
as a percentage of CD4+ or CD8+ cells.  
DTT tests in peripheral blood 
As sputum has to be homogenized before flow cytometry, a possible effect of DTT 
treatment on surface markers has to be considered. However, in contrast to peripheral 





In order to evaluate the influence of DTT on surface markers under study, we performed 
the same procedure of sputum processing using peripheral blood. Half the sample was 
treated with DTT and the other half with PBS alone in the same proportion as that of 
sputum (1g peripheral blood: 4ml DTT or 4ml PBS). Afterwards PBMC were isolated and 
stained as described. 
Data analysis 
Flow cytometry data were acquired and analysed using CellQuest Software (Becton 
Dickinson). Data are expressed as median and range. Wilcoxon signed rank test was used 
for comparison within the same group, and Mann-Whitney U test was used for comparison 
between two groups. A value of p<0.05 was considered significant, at a 95% confidence 
level. 
Statistical analyses were performed using Minitab 14. 
 
3.4.4. Results 
Characteristics of patients 
Fifty allergic asthmatic patients were recruited for this study. 
Success rate in sputum induction was 90%; however, flow cytometry could only be 
performed in 41 of the samples due to insufficient number of T cells (clinical 
characteristics of subjects are given in Table 3). 
Patients with different asthma severities were paired regarding to age and gender. Twenty 
one patients had intermittent asthma and were not under inhaled corticosteroids. They only 
resorted to rescue medication with short acting β2-agonists. Twenty patients had moderate 
persistent asthma; all were receiving beclomethasone dipropionate or equivalent 
(budesonide or fluticasone) daily (median dose 500μg per day), 11 of them were also 










Moderate Persistent  
Asthma (n=20) 
Age (years) 39 ± 15 49 ± 13 
Sex (F/M) 14:5 11:9 
FEV1 (% predicted) 106% ± 12 92% ± 23 
FEV1/FVC 82% ± 7  70% ± 10 
FEF25-75 (% predicted) 85% ± 23 56% ± 26 
Current smokers  3 4 
Blood eosinophils (%) 2.4% ± 2 3.8% ± 3 
Serum IgE (IU/ml) 186 ± 152 500 ± 612 
Results are expressed as mean (± SE) 
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; FEF= forced expiratory flow 
 Sputum processing 
Since DTT may affect results with sputum T cells, we also performed DTT incubations 
with peripheral blood. No differences were seen in staining of any of the cell surface 
markers (CD28, CD25 or CD69) on either CD3+, CD4+ or CD8+ cells between 
peripheral blood samples pre-treated with DTT plus buffer (PBS), and those treated with 
buffer alone (Table 4). 
 
Table 4 – The effect of dithiothreitol (DTT) on the percentage of sputum lymphocytes expressing 
CD28, CD25 and CD69 (n=6) 
 
 CD3+  CD4+  CD8+  





























































Comparison between blood and sputum in all asthmatic patients 
There were significant differences in the CD4/CD8 ratio between sputum and peripheral 
blood (3.6 vs. 2.0 respectively, p=0.005). This difference was due to a decrease in the 
percentage of CD8+ T cells in induced sputum (32.0% vs. 19.5%, p=0.001), with no 
significant change in CD4+ T cell percentages (63.0 vs. 73.5, p=0.056).  
CD8+ T cells can be subdivided into functional and phenotypically different populations, 
on account of CD28 expression. CD8+CD28+ T cells are predominant in young healthy 
individuals and CD8+CD28− cells increase with aging and during inflammation and 
autoimmune disease. In the present study, there were no significant differences in relative 
percentages of CD8+CD28+ and CD8+CD28− T cells between peripheral blood and 
sputum (Figure 16I). Likewise there were no differences in the relative percentages of 
CD4+CD28+ and CD4+CD28- T cells (Figure 16F). 
The relative percentage of total T cells expressing CD25 and CD69 was higher in sputum 
than in peripheral blood (26.9% vs. 21.3% and 57.7% vs. 3.4% for CD25 and CD69, 
respectively; Figs 16A and 16B). Similar results were obtained for CD8+ T cells (11.5% vs. 
5.3% and 74.4% vs. 4.8%, for CD25 and CD69, respectively; Figs. 16G and 16H). In 
contrast, for CD4+ T cells only CD69 expression was higher in sputum when compared to 





Figure 1 – CD25 (panels A, D and G, n=25), CD69 (panels B, E and H, n=28), and CD28 (panels C, 
F and I, n=23) surface expression in peripheral blood and induced sputum T cells from patients with 
intermittent and moderate persistent asthma.  
The median value in each dataset is represented by a horizontal bar. Statistical analysis was 
performed with the Wilcoxon signed rank test. 
 
CD8+ T cells had a lower expression of CD25 and CD28 than CD4+ T cells, both in 
induced sputum (10.4% vs. 25.6% and 55.6% vs. 94.6% for CD25 and CD28 respectively) 
and in peripheral blood (5.1% vs. 30.0% and 61.7% vs. 95.9% for CD25 and CD28 
respectively; Figs 17A and 17C). In contrast, CD8+ T cells had a higher expression of 
CD69 than CD4+ T cells both in sputum and peripheral blood (74.4% vs. 50.8% and 4.8% 
vs. 2.2% respectively; Fig 17B). 
 
Figure 2 – Comparison of surface expression of CD25 (panel A, n=25), CD69 (panel B, n=28)) and 
CD28 (panel C, n=23) between CD4+ and CD8+ T cells from peripheral blood and induced sputum 
of patients with intermittent and moderate persistent asthma.  
The median value in each dataset is represented by a horizontal bar. Statistical analysis was 






Comparison between blood and sputum in patients with intermittent asthma  
To circumvent the possible effect of inhaled corticosteroids, we analysed the data referring 
only to intermittent asthmatic patients without medication, both at the time of sputum 
induction, and in the previous two weeks. We found similar results in these intermittent 
patients as those reported in the whole study population for the expression of activation 
markers in blood and induced sputum (Data not shown).  
Relationship between severity and phenotype in sputum 
Asthma severity was classified according to GINA guidelines and only intermittent or 
moderate persistent asthmatic patients were recruited for this study. To circumvent the 
possible effect of control, we show here results for controlled intermittent and controlled 
moderate persistent asthmatic patients alone. 
There were no significant differences in the percentages of any of the sputum T cell 
subpopulations between patients with intermittent asthma and patients with moderate 
asthma. Likewise, no correlation was found between relative expression in sputum 






Table 5 – Expression of CD25, CD69 and CD28 in sputum total lymphocytes, CD4+ and CD8+ T 
cells from patients with intermittent (n=11) and moderate persistent (n=6) controlled asthma.  
 

























































Results are represented as median percentage and range, and comparisons were performed by the 
Mann-Witney U test. 
 
Nevertheless, a more frequent expression of CD25 on CD8+ T cells from peripheral blood 
was associated with greater disease severity, with moderate persistent asthmatic patients 
having a higher percentage of CD25 positive cells (8.7% vs. 2.1% for intermittent and 




Figure 18 – Expression of CD25 on CD8+ T cells from peripheral blood of patients with intermittent 
(n=18) and moderate persistent (n=8) asthma.  
The median value in each dataset is represented by a horizontal bar.  






Relationship between control and phenotype in sputum 
Asthma control was assessed prior to sputum induction by the ACT test. Asthmatic 
patients were divided into controlled (ACT above or equal to 20 points) or uncontrolled 
(ACT below 20 points) according to test results.  
No correlation was found between relative expression in sputum lymphocytes of CD28, 
CD25 or CD69, and the control of asthma (Table 6). 
 
Table 6 – Expression of CD25, CD69 and CD28 in sputum total lymphocytes, CD4+ and CD8+ T 
cells from patients with controlled (n=6) and uncontrolled (n=6) moderate persistent asthma. 
 
 CD3+  CD4+  CD8+  















































Results are represented as median percentage and range, and comparisons were performed by the 
Mann-Witney U test. 
 
3.4.5. Discussion 
This study clearly shows that, in subjects with allergic asthma, sputum CD4+ and CD8+ T 
cells have a phenotype of activated cells. This might be related to increased production of 
cytokines in the lung and to a hypothetical regulatory or inflammatory function. 
In the present study, we observed higher expression of activation markers in sputum 
lymphocytes than in peripheral blood, consistent with an inflammatory process going on in 
the lung. Interestingly enough, this heightened expression was significant predominantly in 
CD8+ T cells which had higher expression of both early and late activation markers. 
CD8+ T cells are considered to be of lesser importance in bronchial asthma. In contrast, in 
chronic obstructive pulmonary disease (COPD), also an inflammatory lung disease, CD8+ 
T cells contribute to the abnormal inflammatory process, and play an important role in the 
pathogenesis of disease. Increased numbers of activated CD8+ T cells in the airways may 
cause acute tissue damage via the release of lytic substances, such as perforin and 
granzymes.  
CD8+ T cells are important immunoregulatory cells in some animal models of allergic 





tendency towards a high percentage of CD8+ T cells in the BAL of asthmatic patients as 
compared with healthy controls has been shown, resulting in a decreased CD4/CD8 ratio 
114. In fact, activated CD4+ T cells increase and produce type 2 cytokines in the peripheral 
blood, but CD8+ T cells are more sequestred than CD4+ T cells in the airway during an 
acute asthma attack 114.  
 Furthermore, the number of CD8+ cells in bronchial biopsies in patients with asthma has 
been associated with disease outcomes, as determined by loss of lung function 96. Indeed, 
activated CD8+ T cell infiltration in peribronchial tissue has been associated with asthma 
death 112. 
 
In our study, we found a higher CD4/CD8 ratio in induced sputum when compared to 
peripheral blood. Similar results have previously been reported by other investigators 172, 
even in healthy volunteers 174. The imbalance obtained was due primarily to a reduction in 
the percentage of CD8+ T cells. This suggests that this difference may rather be due to the 
sources of the biological fluids, than to the presence or absence of asthma.  
 
In the present study, we did not find any significant differences between the percentages of 
either CD28-expressing CD4+ or CD8+ lymphocytes in sputum and peripheral blood. 
CD28 is a co-stimulatory receptor, constitutively expressed on approximately 95% of 
CD4+ T cells and 50% of CD8+ T cells in humans, and is crucial for activation and 
proliferation of naïve T cells 47. Effector T cells are less dependent on CD28 and their 
survival relies on extrinsic factors, such as IL-2, that are produced during activation 27. This 
may suggest that T cells found in the lung in the context of asthma are not different from 
those in peripheral blood, in terms of co-stimulatory requirements.  
 
We show here that in both total CD3+ cells and CD8+ T cells, CD25 and CD69 are 
expressed in a higher relative percentage in sputum than in peripheral blood.  CD25, the 
interleukin-2 receptor α-chain, is a marker of both T cell activation and proliferation. 
CD69, which can be induced in different leucocytes, such as T cells, eosinophils, and 
neutrophils, is an early marker of T cell activation.  
Leckie et al. reported similar results to ours: both in asthmatic patients and healthy controls 
CD8+ T cells from sputum had higher percentage of CD69 expression than CD4+ cells 
174. There were also higher percentages of both CD4+ and CD8+ cells expressing CD69 in 





anti-CD3 mAb. Instead, they used anti-human CD45 mAb to exclude other non-leucocyte 
events. This might lead to the inclusion of CD8+ NK cells in the analysis. Moreover, the 
Leckie study only included eight “very mild” asthmatic patients, while in the present study, 
41 asthmatic patients with different degrees of severity were studied. In another report, 
Ortega et al. assessed the presence of activated bronchial lymphocytes in induced sputum of 
asthmatic patients and healthy controls. Lymphocytes from asthmatic patients showed an 
increased surface expression of activation markers (CD25 in T cells, and CD23 in B cells) 
when compared to lymphocytes of healthy non-atopic subjects 180. However, this study 
only evaluated total T cells, while in our study we analysed both CD4+ and CD8+ 
subpopulations. 
Our previous results could have been influenced by sputum processing using DTT. 
However, we believe that this is not the case because adding the same concentration of 
DTT, as used in sputum processing protocol, to whole blood from six allergic asthmatic 
patients did not influence the expression of the markers under study. Furthermore, other 
studies have also shown that DTT has no effect on the expression of CD69 and other 
surface markers 174, 181. 
 
The GINA guidelines classify asthma severity in four degrees, from mild intermittent to 
severe persistent 177. In the present study, we recruited two groups of asthmatic patients: 
one group with intermittent asthma and another group with moderate persistent asthma. 
Intermittent asthmatic patients were not on regular medication (only rescue medication), 
and all moderate persistent asthmatic patients were on inhaled corticosteroids. 
We could not observe any relationship between asthma severity and the percentage of total, 
CD4+ or CD8+ T cells expressing the surface markers under analysis in induced sputum. 
In contrast, CD25 expression was increased on CD8+ T cells from peripheral blood of 
moderate persistent as compared to intermittent asthmatic patients. 
Our results in induced sputum are not in agreement with those from a previous report. 
Hamzaoui et al. studied, for the first time, the expression of CD28 on CD8+ T cells in 
induced sputum. CD8+CD28- cells were found to be more expanded and expressed lower 
levels of IFN-γ in severe asthmatic patients than in mild asthmatic patients and age-
matched healthy controls 182. However, the authors did not include CD3 in the flow 
cytometric evaluation, including as CD8+ T cells probably other non-T cells (namely NK 





Reasons that may account for our failure to observe a relationship between asthma severity 
and parameters analysed in sputum in our study may include the fact that patients with 
moderate asthma were on inhaled corticosteroids. In fact, treatment with inhaled 
corticosteroids could have had a confounding effect on analysis of airway inflammation, as 
it has been demonstrated to reduce expression of some activation markers 108, 183. 
Alternatively, disease severity may rather be related to changes in function than in the 
percentage or phenotype of CD8+ T cells in the bronchi of patients with asthma. 
 
Independently of disease severity it is important to monitor control of disease. 
Monitorisation of disease control can be performed using both clinical scores and lung 
function testing. However, more patient-dependent tests of control, such as the ACT are 
increasingly being used. In this regard it should be stressed that clinical control is, to a 
certain extent, related to control of bronchial inflammation. The most frequently used 
marker of airway inflammation is sputum eosinophil percentage, since eosinophils are a 
good marker of impending loss of asthma control, and their increase is significantly 
associated with symptoms 173, 184. However, some asthma exacerbations in optimally treated 
patients are mild and non-eosinophilic, so they cannot be monitored by eosinophilic cell 
counts 185. 
Instead of using eosinophils, in the present study, we evaluated the possible correlation 
between T cell subpopulations and their activation status, and asthma control, as assessed 
by the ACT. For clarity of results we show here only the results for controlled and 
uncontrolled moderate persistent asthmatic patients. 
No association was found between relative expression in sputum lymphocytes of CD28, 
CD25 or CD69, and the control of asthma. As previously discussed for disease severity, it 
is possible that this lack of association was due to the fact that all moderate persistent 
asthmatic patients were taking inhaled corticosteroids. Studies with a different design, 
allowing suspension of medication may help to clarify this issue. 
 
In summary, in this study, we show that T cells are activated in the lung, which may suggest 
that both subpopulations are participants in the inflammation process at the target organ. 
However, we have not been able to demonstrate a relationship between activation of T cell 
subsets and severity of asthma or asthma control. Further studies are needed in order to 
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4.1. Demographic aspects 
 
The prevalence of allergic diseases is increasing in most countries of the world, particularly 
in areas with previously low or medium levels of prevalence 186. A large number of papers 
have been published over the past years extending our knowledge on the epidemiology, 
diagnosis, management and co-morbidities of allergic diseases.  
Data regarding prevalence and sensitisation profiles in bronchial asthma and rhinitis are still 
scarce in Portugal. Nevertheless, the prevalence of allergic diseases in this country 
increased between ISAAC phases I and III (7 years apart), both in allergic 
rhinoconjunctivitis and bronchial asthma in the two age groups under study (6-7 years and 
13-14 years) 186. Data in adults is restricted to the ECRHS study in volunteers between 
20-44 years old, which showed an estimated prevalence of 5% for bronchial asthma and of 
17% for rhinitis 124. 
Several regional 118, 129, 131, 187 and one Iberian study 130 evaluated the sensitisation profiles, 
prevalence and disease severity in asthma and rhinitis in Portugal. However, they were 
either only questionnaire based 118, 187, included data of a private clinic practice 129, 131, or 
were not specifically carried out in the Cova da Beira region 130. 
In order to increase our present knowledge of the demographic aspects of the main allergic 
diseases in Portugal, we collected data from patients attending the Allergy Clinic of the 
Cova da Beira Hospital Centre.  It is important to stress that in the first Portuguese pollen 
map, carried out in the country between 1998 and 1999, the Cova da Beira region had the 
highest pollen counts in Portugal (Mapa Polínico em Portugal (1998-1999), 
SPAIC/Schering-Plough). Surprisingly, the region is not included in the “Rede Portuguesa de 
Aerobiologia” (www.rpaerobiologia.com), and no station/monitoring centre exists nearby. 
This should be a goal for the near future. 
 
All patients with diagnosed asthma and/or rhinitis were included for further study. The 
asthma study (Paper I) included patients admitted to the Allergy Clinic between 2003 and 
2006 (1078 patients); whereas the rhinitis study (Paper II) comprised patients admitted to 
the Allergy Clinic between 2003 and 2007 (1092 patients). Both referral patients and newly 





Exclusion criteria included patients under 18 years of age, patients not currently living in 
the area, and patients with discordant results in specific allergy tests.  
We diagnosed asthma and rhinitis by positive history and examination, backed up by lung 
function testing and specific allergy tests (skin prick test and serum-specific IgE). 
According to IgE involvement, two broad categories were considered: allergic and 
non-allergic. We applied current guidelines for the classification of this type of pathology 
regarding severity and control aspects, including both the severity of symptoms and quality 
of life outcomes. Another important aspect was that we considered co-morbidities of 
bronchial asthma and rhinitis, and applied the concept of “one airway one disease”. More 
specifically, patients with rhinitis were evaluated for asthma by history, chest examination 
and assessment of airway obstruction. On the other hand, patients with asthma were 
evaluated for rhinitis by history and physical examination, including anterior rhinoscopy. 
 
Thirty percent of our asthmatic patients and twenty eight percent of our rhinitis patients 
were non-allergic. Non-allergic asthmatic patients were older, predominantly female, and 
had a higher prevalence of drug allergy/drug intolerance. This is in agreement with 
previous reports in other countries 125, 139. 
 
We used anterior rhinoscopy to detect and characterise nasal polyposis. This is of especial 
interest, since nasal polyps can significantly decrease the quality of life of patients with 
rhinitis and worsen concomitant bronchial asthma. In fact, in our study, there was a trend 
for AR patients with nasal polyposis to have bronchial asthma. In contrast, in rhinitis 
patients, who had moderate/severe disease, the prevalence of polyposis was low. This was 
probably due to the fact that the diagnosis of polyposis was based on anterior rhinoscopy 
and not all patients underwent nasal endoscopy, which might have underestimated the true 
prevalence of nasal polyps. 
 
Interactions between the lower and the upper airways are well known and have been 
extensively studied since the 1990s. This eventually led to the development of the ARIA 
project and to the elaboration of specific guidelines on the subject 136, 188. It is reported that 
over 80% of asthmatic patients have rhinitis and 10-40% of patients with rhinitis have 
asthma 136. 
In terms of this association, in our population (Paper I), rhinitis was more frequently 





more frequently associated with NAR than with AR, although, overall, there were more AR 
patients with asthma (Paper II). Reasons that account for this may include the fact that 
allergic rhinitis may precede the development of asthma in a typical allergic march in adults; 
furthermore, immunotherapy in allergic rhinitis patients may delay or even prevent the 
development of further sensitisations and of bronchial asthma. In contrast, non-allergic 
rhinitis and asthma may share common triggers, even if they do not follow a specific 
timeline. Finally, there was only a partial overlap between our patients with mainly rhinitis 
(Paper I) or asthma (Paper II). 
 
Besides analysing the differential association between rhinitis and asthma in allergic or 
non-allergic contexts, it is quite important to ascertain the severity of both rhinitis and 
asthma. In this regard, neither allergic nor non-allergic asthma (nor rhinitis) could be 
differentiated in terms of the severity of clinical symptoms. This is somehow unexpected, 
as it is commonly thought that non-allergic diseases are more severe. This may be due to 
the fact that there were fewer patients with the non-allergic forms of these diseases, thereby 
not allowing a fully balanced analysis of results. In addition, one must keep two aspects in 
mind: firstly, disease severity increases with age, and secondly, non-allergic patients are 
older. Thus, apparently, non-allergic diseases will appear as more severe if we do not pair 
the samples for age. 
 
Sensitisation to aeroallergens was assessed by skin prick testing and/or serum specific IgE 
determination. Skin prick testing was not performed in cases of severe skin disease or if a 
very exuberant reaction was expected. Dermographism and inconclusive skin prick tests 
(such as negative reaction to Histamine) excluded skin test results from further analysis. 
Skin prick testing included a battery of 14 single extracts or extract mixtures from the 
supposedly most prevalent allergens in the area, reaching a total of 35 aeroallergens. 
The major allergens in the area were grass pollen, cereal pollen, mites and olive tree pollen. 
Monosensitisation was uncommon and it mainly included mites. This sensitisation pattern 
was similar for asthmatic and allergic rhinitis patients. 
Frequency of sensitisation evaluated by specific IgE was slightly different but directly 
correlated with that from the skin prick tests. This finding has two main causes: firstly, for 
some patients, data on both skin prick testing and specific IgE were unavailable; secondly 
even after correcting for this bias by selecting only patients with both exams, the skin prick 





Interestingly enough, in spite of similar prevalence within the major allergens, a particular 
species or family seems to be preferentially associated with high levels of specific IgE. This 
was the case of grass pollen (Poaceae family), both one of the major allergens and the one 
with the highest levels of sensitisation. This is in accordance with previous studies in 
Portugal 129, 131 and the Iberian Peninsula 130, reporting common polysensitisation involving 
mites and pollens. However, these studies evaluated only severity, prevalence, and 
sensitisation with only minor emphasis on clinical aspects. Moreover, sensitisation was 
evaluated by skin prick test alone.  
In our study, correlation between specific IgE levels and severity of the disease was not 
found possibly due to the polysensitisation profile of most of the volunteers. Nevertheless, 
it has also been described that specific IgE levels do not often directly correlate with 
clinical symptoms 189, 190, 191. 
 
Epidemiological studies carried out in different geographical regions of the world have 
shown a significant and consistent association between levels of airborne pollutants (diesel 
exhaust particles, ozone, nitrogen dioxide, and sulphur dioxide) and increased asthma and 
rhinitis symptoms 132. The prevalence of atopy and allergic rhinitis is higher in urban than in 
rural areas, both due to increased air pollution and protective farm effect. 
In urban areas, pollen grains can become coated with fuel residues and combustion 
products, and this binding of pollen to diesel exhaust particles may modulate the allergenic 
epitopes and increase their allergenicity 132. Moreover, nonspecific irritants such as air 
pollution may aggravate symptoms in symptomatic patients and induce symptoms in 
asymptomatic patients. 
Urban- and rural-based asthmatic patients in our study had different sensitisation profiles, 
but could not be differentiated in terms of severity of their disease. In contrast, urban and 
rural-based AR patients had similar sensitisation profiles. 
Our findings may be related to the relative size of the sensitiser particles, and to how deep 
they can travel through the airways. In fact, intact pollen grains (10 to 100μm on average) 
do not typically enter the lower regions of the respiratory tract, and main symptoms are 
located in the eyes, nose and nasopharynx 155. In our specific population, most of the 
patients, both asthmatic and AR, were sensitised to Poaceae pollen, which have pollens 
varying from 20-80μm, with cultivated ones (cereals) having larger pollens. Provocation 
tests with allergen could be a way to clarify this issue, especially because there is 






One limitation of our studies is that the sample of adults we analysed was drawn from a 
specialised allergy practice. In this sense, it may differ significantly from the general 
population of patients with rhinitis and asthma, since patients treated by specialists appear 
to have more severe symptoms than those seen by general practitioners. In fact, many 
rhinitis patients dismiss the disease. In addition, severity of asthma and rhinitis patients in 
our studies was classified at the first appointment, even though many of them were not 
treatment-naïve at that time.  
Moreover, as patients were selected by presenting rhinitis to the rhinitis study and by 
presenting asthma to the asthma study, there is a certain degree of overlap among the 
groups. However, it is important to notice that the majority of the population enrolled for 
the rhinitis study had moderate/severe disease (82% in the allergic rhinitis group and 80% 
in the non-allergic rhinitis group), and was most likely referred to the Allergy Clinic by its 
rhinitis symptoms. In contrast, a similar trend was not seen in the asthmatic patients, as the 
majority of the population under study presented intermittent (52% in the allergic rhinitis 
group and 45% in the non-allergic rhinitis group) or mild persistent disease (29% in the 
allergic rhinitis group and 34% in the non-allergic rhinitis group).  
Nevertheless, from our point of view, this is a very interesting study as it included clinical 
parameters, in contrast to previous studies that were mainly questionnaire-based. As the 
clinical definition of the diseases is difficult to use in the epidemiological settings of large 
populations, the questionnaires use simpler “working definitions”, that are less specific. 
Our study could have been improved had we had access to auxiliary diagnostic testing, 
namely endoscopy and rhinomanometry for rhinitis evaluation and eNO for asthma 
assessment. The first methods are usually reserved for ENT (ear, nose and throat) 
outpatient clinics; the latter one is not currently available at the Hospital, in spite of a 
try-out period with one such system in the Lung Function Testing Unit.   
 
As a result of the demographic studies, we developed a thorough patient database, useful 
for studying the cellular aspects of allergic pathologies. We believe that the sensitisation 
profiles will increase the specificity of the coming evaluations, and will serve to direct 
avoidance strategies and even landscape planning. 
In addition, these studies reinforced the need to treat the upper and lower airway diseases 






4.2. CD8+ T cells in allergy 
 
In both allergic asthma and rhinitis, there is chronic inflammation of the respiratory tract, 
which is mediated by the increased expression of multiple inflammatory proteins, including 
cytokines, chemokines, adhesion molecules, and inflammatory enzymes. In both diseases, 
there are acute episodes or exacerbations, when the intensity of this inflammation 
increases. Several studies have suggested a role for T cells in asthma, as T cell infiltration is 
a feature of the late-phase response to allergen in the lung. By specific immunostaining of 
bronchial mucosal biopsies, obtained via the fiberoptic bronchoscope, T cells could be 
identified, as well as the mRNA for the cytokines they may secrete. 
In asthmatic patients, there is an increase in the number of CD4+ T cells in the airways, 
which are predominantly Th2 cells 192. Th2 cells have a central role in allergic inflammation 
by secreting the cytokines IL-4, IL-5, IL-9 and IL-13. IL-4 and IL-13 drive IgE production 
by B cells, IL-5 is responsible for eosinophil differentiation in the bone marrow and 
enhances their effector capacity; and IL-9 attracts and drives the differentiation of mast 
cells. 
On the other hand, CD8+ T cells are considered to be much less important, although a 
number of studies describe a role for these cells in the development of AHR and airway 
inflammation 95, 97, 100. In asthma patients, airway infiltrating CD8+ T cells have the capacity 
to produce Th2 cytokines and modulate the disease 11, increased numbers of CD8+ T cells 
have been found in the lungs of patients after a fatal asthma attack 112, and the number of 
bronchial wall CD8+ T cells, but not the number of eosinophils or thickness of the 
basement membrane, was found to correlate significantly with decline in lung function 96. 
The precise role of CD8+ T cells in allergic inflammation is still elusive, and it might be 
that different CD8+ T cell populations exert different functions. Moreover, CD8+ T cell 
function may be different between the sensitisation phase and the actual disease.  
Atopy can be assessed by studying specific IgE levels in serum; it is likely that allergic 
disease encompasses other alterations at the T cell level in peripheral blood, not only 
restricted to the target-organs. With our project, we aimed at studying CD8+ T cells in the 
peripheral blood of atopic volunteers with allergic diseases (Paper III). As a subpopulation 





disease settings in vivo and in vitro, we studied CD28 positive and negative CD8+ T cell 
populations independently. 
Atopy was not related to an altered relative percentage or specific phenotypes in 
CD8+CD28+ or CD28− human T cells. However, freshly immunomagnetically isolated 
CD8+CD28+ or CD28− human T cells had distinct phenotypes and, although sharing 
similar cytokine production patterns, they proliferated at different levels to common 
stimuli. Proliferation to the allergen extract Der p was also differential, as only CD8+CD28- 
proliferated in response to Der p in the presence of APC.  
It would be important to repeat this study with different allergens, especially so because 
house dust mite allergen has proteolytic activity. This activity is responsible for augmenting 
the permeability of pulmonary epithelium, thereby contributing to the uptake of the 
allergens and increasing the likelihood of developing an allergic response 193. Thus, in this 
case, the biological activity of the allergen enhances its allergenicity in vivo. In in vitro 
systems, the mitogenic potential may also be influenced by the enzymatic activity, although 
no studies on this aspect have been published. 
 
Both CD8+ T cell subpopulations showed similar proliferation capacity in atopic and 
non-atopic individuals, and did not show suppressor capacity. One must bear in mind that 
this assessment roughly mimics the real stimuli in vivo, as in a setting of allergic disease the 
stimuli are not punctual, but more or less continuous over long periods of time. It can also 
be argued that peripheral blood T cells do not share the same cellular environment as their 
counterparts at the target organs. Furthermore, allergen contact is much more limited.  
In fact, previous studies with unprimed CD8+CD28− T cells from the peripheral blood 
showed that these cells do not have regulatory properties, and do not express markers 
related to suppression 56.  
To clarify the potential suppressive function of the CD8+ T cells, we aimed at developing 
allergen-specific T cell lines. With that approach, we were expecting to develop both 
allergen-specific Th2 and CD8+ cell lines, studying the suppressive potential through a 
co-culture system. This still remains an ongoing project, as until today, we were unable to 
obtain a cell line with the allergen extracts we have used (Appendix). 
 
T cells in peripheral blood may not be a mirror image of their counterparts at the target 





possible that once at the target-organ, CD8+ T cells do not return to the peripheral blood, 
and allergen-induced specific features cannot be “seen” there.  
In fact, some researchers believe that even in non-atopic asthmatic patients a IgE-mediated 
response develops only at the target-organ, as both phenotypes (allergic and non-allergic) 
cannot be distinguished in terms of clinical and pathophysiological features 125, 194. 
Thus, a regulatory potential of CD8+ T cells in allergy can only be denied after carefully 
studying organ-based CD8+ T cells. So far, suppressor functions of CD8+ T cells in 
humans have been found in disease setting encompassing massive antigen stimulation, such 
is the case of transplanted patients 195. 
 
We, therefore, went on to study CD8+ T cells at the target-organ, verifying not only their 
presence, but also the activation-status in asthmatic patients. CD8+ T cells from the lung 
could have been obtained from bronchoalveolar lavage fluid, but we chose induced sputum 
instead, as this is a far safer method and also non-invasive. Sputum cells are derived mainly 
from the central, more proximal airways; while cells from BAL and bronchial washing 
(BW) sample more peripheral airways and the alveolar compartment. Nevertheless, cellular 
sputum composition correlates well with that found both in BAL and BW. 
 
In our sputum study, (Paper IV), we show that CD8+ T cells are activated, which may 
suggest that they are participants in the inflammation process in the target organ. As 
inflammation is related to disease severity, we further evaluated activation markers in 
allergic asthmatic patients with different degrees of disease severity. We were unable to 
demonstrate a relationship between activation of T cell subsets and severity of asthma or 
asthma control.  
The main problem in the study design was the ethical impossibility to withdraw inhaled 
corticosteroids from more severe patients. Ideally, all study volunteers should be without 
corticosteroid medication for at least two weeks, controlled only by inhaled β-agonists.  
As corticosteroids influence the expression of activation markers, they could mask 
expected differences 108, 183. Hence, it would be important to repeat the study without 
interfering medications in a closely monitored setting. 
This same problem also influenced our evaluation on control. A thorough analysis should 
be made by evaluating control and specific subpopulations and activation markers in a 
population of asthmatic patients with the same disease severity. Furthermore, if 





dosages of corticosteroids, apart from being paired regarding age, gender and disease 
severity. We performed such an analysis in a small sample of intermittent asthmatic patients 
that were only on beta-blockers. However, no significant differences were found, either in 
terms of subpopulations, or in terms of activation markers. 
We have studied CD8+ T cells only in asthmatic patients, since we could not obtain any 
suitable sputum sample from a wide sample of normal controls. Therefore, we cannot 
exclude the possibility that CD8+ T cells may also be activated in the sputum of healthy 
controls, although it is unlikely, as suggested by Ortega et. al, who assessed the presence of 
activated bronchial lymphocytes in induced sputum from asthmatic patients and healthy 
controls 180. However, Leckie et al. failed to demonstrate a significant difference between 
the relative expression of CD69 in CD8+ T cells from the induced sputum of mild 
asthmatic patients and healthy controls 174. 
A thorough study of several other phenotypic markers and a functional study were 
impossible to perform, as CD8+ T cells existed in a reduced percentage in the induced 
sputum samples. The percentage of CD8+ T cells in the peripheral blood is approximately 
30% of all T cells in the peripheral blood, decreases in induced sputum and the CD4/CD8 
ratio increases even more in asthmatic patients, as the disease is mostly Th2 mediated. 
 
In summary, in this thesis, we have clarified the demographic characteristics of the 
asthmatic and rhinitis patients of the Allergy Clinic of the Cova da Beira Hospital. 
Furthermore, we have characterised T cells, especially the subgroup of CD8+ T cells, both 
phenotypically and functionally in allergic patients. Finally, we have attempted to devise 
novel strategies to isolate peripheral blood T cells and to derive allergen-induced T cell 
lines. Regarding our hypotheses, firstly, freshly isolated peripheral blood CD8+ T cells 
were unable to inhibit proliferation and cytokine synthesis of CD4+ effector T cells 
induced by the exposure to Der p extract. Secondly, induced sputum CD8+ T cells from 
asthmatic patients were activated, expressing higher relative percentages of the activation 
markers CD25 and CD69 when compared to CD8+ T cells from the peripheral blood. 
Thirdly, although activated, CD8+ T cells activation in induced sputum from asthmatic 

















5.1. Isolation of Leucocytes from Depletion Filters 
 
Introduction 
Peripheral blood CD8+CD28− T cells exist in a variable percentage (up to 40% of all CD8+ 
T cells). The great majority of studies performed to date used buffy-coats or freshly drawn 
peripheral blood as a source of lymphocytes. In order to obtain functional leucocytes for 
performing the cell culture studies and implement the new methods, we tried a method 
using leucocyte depletion filters. These blood product preparation units are normally 
employed by blood banks to prepare a leucocyte-poor blood product and are commonly 
discarded after use.  
This procedure is the object of two United States Patents that we used as reference: 
Kuroda et al. United States Patent number 4416777 196 and Rashidbaigi et al. United States 
Patent number 5989441 197. The first patent describes a multi-step process to facilitate 
removal of red blood cells from leucocytes using a variety of elution solutions: phosphate 
buffered saline (PBS) in combination with polyvinyl-pyrrolidone, sodium casein, 
polyvinyl-alcohol or gelatine 196. The second patent involves isolating leucocytes from filters 
which have been used to purify red blood cells or platelets back-flushing the used filters 
with a haemolysis solution, such as cold ammonium chloride, and collecting the functional 
human leucocytes 197. Using this method, the recovery from Leukotrap™ filters was 
between 6 and 8x108 leucocytes per filter unit, i.e. a 30-40% recovery of total leucocytes. 
The viability was more than 95%.  Leucocytes recovered by the claimed method were 
functional, i.e., the cells were capable of being activated by virus or mitogen to produce 
cytokines, such as interferon, or other immunomodulators. Both methods require 
processing the filters within 24 hours after blood collection; otherwise the viability of the 
leucocytes is greatly impaired. 
Several authors published alterations to these patents in scientific journals 198. Based upon 






Materials and Methods 
Filters were maintained at 4°C until used and processing was always within 24 hours after 
blood collection. Each filter was back-flushed eight times with red cell lysing solution 
(ammonium chloride 0.83%) using a 60ml syringe. The collected suspensions were divided 
into two fractions, the first fraction containing the first four and the second fraction the 
last four suspensions. In order to remove red blood cells, the eluted leucocyte preparations 
were further purified in a density gradient using Lymphoprep™ (Axis-Shield). The 
nebulous phase was collected, washed twice in fresh PBS and incubated overnight in Petri 
dishes in RPMI complete medium. The non-adherent fraction was collected, washed and 
counted in a haemocytometer by the Trypan blue exclusion method.  
In order to evaluate purity (as well as size and granularity) obtained leucocytes were 
acquired in a FACSCalibur. 
 
Results and Discussion 
The process of isolating leucocytes from depletion filters was developed in order to isolate 
a great amount of leucocytes from a usually discarded material.  Prior methods have been 
reported in which leucocytes which remain trapped behind in the filter units have been 
recovered. For example, one method involves back-flushing five times with 50 mL PBS at 
4° C using a 60 mL syringe (R. Longley et al, J. Immuno. Methods, 121:33-38 (1989)). By 
applying our modified method, we expected to retrieve functional leucocytes free from 
erythrocytes and platelets from the recycled filters. However, our results were 
disappointing. 
Obtained fractions were always contaminated with leucocytes other than lymphocytes and 
monocytes, even after separation over Lymphoprep™  (Figure 19) and overnight 
adherence to plastic (Figure20). Moreover, lymphocytes had different characteristics 
regarding forward and side scatter when compared to lymphocytes isolated from freshly 
drawn peripheral blood. Leucocytes obtained were very “sticky” to plastic and glass 
surfaces and between them. Besides all this we had low recoveries of leucocytes. 
Although we used fluorochrome-conjugated anti-CD3, anti-CD4, and anti-CD8 
monoclonal antibodies for confirmation purposes, we did not evaluate viability. This could 





that the leukocytes obtained may be necrotic or apoptotic cells. This might explain their 
different forward and side scatter characteristics. 
 
 
Figure 19 – Flow cytometry dot plots of filter mononuclear cells. 
Obtained fractions were contaminated with granulocytes even after density gradient centrifugation 
and overnight adherence to plastic.  
Panel A depicts a dot-plot from whole peripheral blood; Panel B depicts the first fraction of the 
recovered leucocytes at the end of the procedure. 
 
 
Figure 20 – Overnight adherence to plastic increases purity of leucocyte depletion filters’ fractions.  
After density gradient centrifugation, cells were allowed to adhere to a Petri plastic dish overnight. 
The non-adherent fraction was collected and after one washing step cells were passed through a flow 
cytometer. Panels A and B depict the first and second fractions respectively after density gradient 







After careful analysis we abandoned the process in favour of freshly drawn peripheral 
venous blood. The latter circumvents our problem of scarce and contaminated fractions of 
mononuclear cells, since it allows simpler, quicker and purer isolations. Furthermore, it 
only implies a small discomfort to the volunteers. The drawback was that we needed more 




Meyer et al. published an alternate method for leucocytes elution in the Journal of Immunological 
Methods in late 2005 199. The method was published when we were already using freshly drawn 
peripheral blood and we did not try it. The main difference is the use of a supplemented filter 
elution medium (PBS without Mg2+ or Ca2+ containing 5mM of EDTA-Na2 and 2.5% sucrose) 
leading to higher cell yields. However, the total leucocyte recovery with this method is low 
compared to whole blood, and also lower than in standard buffy coats. Relative recoveries for 
lymphocytes and monocytes are higher than for total leucocytes, which makes the method 
interesting as yet another source of mononuclear cells.  
The method led to a European Patent (EP1484390) “Methods of preparing peripheral stem cells 
from leucocyte reduction filters” application. The last event published (06/02/2008) was that 
the application deemed to be withdrawn because the reply to the examination report was not 








5.2. Generation of Allergen-specific T cell lines 
 
Introduction 
Allergic diseases are associated with an influx of inflammatory cells such as eosinophils and 
T cells into target-organs. Allergen-specific T cells seem to orchestrate the whole allergic 
process through the production of various mediators (such as IL-4, IL-5, IL-9 and IL-13), 
as well as cell-to-cell contact. The relative importance of the various subpopulations of T 
cells has not been fully addressed in allergic disease. 
Allergen-specific T cells exist in very small numbers in the peripheral blood and 
allergen-specific proliferative responses are usually weak, making it hard to manipulate the 
specific response and measure the actual regulatory or suppressor functions. As we have 
previously shown, CD8+ T cells are able to proliferate, albeit weakly, in response to Der p 
extract. 
In order to better clarify the role of the CD4+ and CD8+ T cell populations in allergic 
atopic diseases, it is important to develop allergen-specific T cell lines that will allow the 
study of the finer functional details of these cells. Our aim was to generate allergen-specific 
human T cell lines, specific for the major aeroallergens in the Cova da Beira region, namely 
Graminea pollens. 
 
Materials and Methods 
Subjects 
Atopy was assessed by positive skin prick tests and specific IgE levels to common 
aeroallergens. Volunteers who received immunotherapy or were on systemic medication 
were excluded. Pregnant or breastfeeding women and all volunteers with disease affecting 
the immune system were also excluded. Informed written consent was obtained from all 







Leti provided us with the following Phleum pratense extracts: 
 
L extract   LP extract    B extract 
S-319/L   65-06/LP    S-319/L 
16/09/2002   01/06/2006    16/09/2002 
Cad. Sep 2007   Cad. 31/05/2011   Cad. Sep 2007 
130,8 mg   137,7 mg    130.8 mg 
S319/02  4834/16       P 185.4 HEP/mg 
 
 
Peripheral blood was collected from 8 adult atopic volunteers all sensitised to Phleum 
pratense. 
Density gradient isolated PBMC were cultured at a concentration of 1x106 cells/ml in 
triplicates in RMPI 1640 complete medium [RPMI 1640, 2mM L-glutamine, 1% 
antibiotic/antimicotic (Sigma-Aldrich, St Louis, MO, USA), and 5% foetal calf serum 
(Biochrom, Berlin, Germany)] in  96-well flatt-bottomed plates (Nunc, Roskilde, Denmark) 
with or without several different concentrations of  L or LP extract (3, 10, 30, 50, 100,  and 
300µg/ml of extract) for 4, 5, 6, or 7 days. For positive control, cells were incubated with 
5µg PHA (Sigma-Aldrich) in the same conditions as for the extracts. Fourteen hours before 
the end of the culture [3H]-thymidine was added to the wells (1µCi/well). [3H]-thymidine 
(Amersham Biosciences, Uppsala, Sweden) incorporation was determined by scintillation 
counts in a TopCount (PerkinElmer, MA, USA) after harvest and results were expressed as 
counts per minute (cpm). Mean cpm of the triplicate cultures and standard error of the 
mean were calculated. 
 
Results 
After performing the cell cultures with the PBMC obtained from the atopic volunteers 
sensitised to Phleum pratense cells were harvested and proliferation was determined by 
[3H]-thymidine incorporation. We did not observe proliferation for the cultures stimulated 





the positive culture control originated significantly high proliferation. The B extract seems 
to be toxic to the PBMC as no proliferation was observed.  
Other allergen extracts were also provided to us with similar results. 
























































































Figure 21 – Proliferation of PBMC to Phleum pratense extracts. 
Isolated PBMC from 6 atopic volunteers were incubated for 4, 5, 6, 7, or 8 days in 96-well 
flat-bottomed plates with and without different concentrations of Phleum pratense L, LP, and B 
extracts. Phytohemaglutinin was used as a positive control (5μg/ml). Tritiated thymidine 
(1μCi/well) was added 14 hours prior to the end of the culture. Cells were harvested onto fibre filters, 
and incorporated thymidine was determined by scintillation counting. Results show thymidine 





Discussion and Conclusions 
With this study we intended to use the allergen-specific T cell lines for allergen-induced 
proliferation and suppression studies. We also aimed at evaluating the suppressor 
properties of CD8+ T cells on allergen-induced cytokine synthesis. 
Allergen-specific T cell lines established from allergic patients provide the opportunity to 
investigate the function and characteristics of T cells responding to allergens 200, 201 and 
determine the influence of substances which may modulate T cell functions 202. 
Developing allergen-specific T cell lines is a very complicated process, since the frequency 
of allergen-specific T cells in PBMC tends to be low. Thus, allergen responses are usually 
quite weak and the concentration of allergen required to get proliferation is often high, 
especially when we compare it with other antigens. Bearing this in mind we carefully 
selected the volunteers and the allergens, including only dialysed allergens. 
One limiting factor could have been the use of fetal calf serum instead of human AB 
serum, as it was referred in previous published studies, since it can lead to diminished 
proliferations. 
All volunteers under study were highly sensitive to Phleum pratense, as assessed by skin prick 
test and serum-specific IgE. However, the extracts under test did not induce proliferation 
on PBMC isolated from the peripheral blood of those patients. All the volunteers tested 
had high total IgE (above 400 UI/ml), were at least class 3 for specific IgE (>3.5 KUA/l) to 
P. pratense, and had a clinical history compatible with P. pratense related allergic disease. 
One must bear in mind that, as in skin prick tests, the presence or absence of specific IgE 
in the serum is not directly associated with the presence of allergen-induced symptoms, 
and, in fact, many symptom-free subjects have detectable allergen-specific IgE levels in the 
serum. Furthermore, in symptomatic subjects the titre of allergen-specific IgE in the serum 
is usually unrelated to the severity of symptoms, as severity depends not only on IgE 
antibodies, but also on the releasability of mediators, on the response of the target organ to 
mediators and on non-specific hypersensitivity 188.  
It could be expected that this lack of correlation might also exist between specific IgE 
serum levels and allergen-specific T cell proliferation in vitro. It may also be that a good 
regulatory response exists and depleting the PBMC of regulatory/suppressor T cells may 
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